1
|
Verhenne S, McCluskey G, Maynadié H, Adam F, Casari C, Panicot-Dubois L, Crescence L, Dubois C, Denis CV, Lenting PJ, Christophe OD. Fitusiran reduces bleeding in Factor X-deficient mice. Blood 2024:blood.2023023404. [PMID: 38620079 DOI: 10.1182/blood.2023023404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 03/15/2024] [Accepted: 04/02/2024] [Indexed: 04/17/2024] Open
Abstract
Factor X (FX)-deficiency is a rare bleeding disorder manifesting a bleeding tendency caused by low FX activity levels. We aimed to explore the use of fitusiran (an investigational siRNA that silences antithrombin expression) to increase thrombin generation and the in vivo hemostatic potential under conditions of FX-deficiency. We therefore developed a novel model of inducible FX-deficiency, generating mice expressing <1% FX activity and antigen (f10low-mice). Compared to control f10WT-mice, f10low-mice had 6- and 4-fold prolonged clotting times in Prothrombin Time- and activated Partial Prothrombin Time-assays, respectively (p<0.001). Thrombin generation was severely reduced, irrespective whether tissue factor or factor XIa was used as initiator. In vivo analysis revealed near-absent thrombus formation in a laser-induced vessel injury-model. Furthermore, in two distinct bleeding models, f10low-mice displayed an increased bleeding tendency compared to f10WT-mice. In the tail-clip assay blood loss was increased from 12±16 microliter to 590±335 microliter (p<0.0001). In the saphenous vein puncture (SVP)-model, the number of clots generated was reduced from 19±5 clots/30 min for f10WT-mice to 2±2 clots/30 min (p<0.0001) for f10low-mice. In both models, bleeding was corrected upon infusion of purified FX. Treatment of f10low-mice with fitusiran (2x10 mg/kg at one-week interval) resulted in 17±6% residual antithrombin activity and increased thrombin generation (4-fold and 2-3-fold increase in endogenous thrombin potential and thrombin peak, respectively). In the SVP-model, the number of clots was increased to 8±6 clots/30 min (p=0.0029). Altogether, we demonstrate that reduction of antithrombin levels is associated with improved hemostatic activity under conditions of FX-deficiency.
Collapse
Affiliation(s)
| | | | | | | | - Caterina Casari
- Université Paris-Saclay, INSERM, Hémostase inflammation thrombose HITH U1176, Le Kremlin Bicetre, France
| | | | - Lydie Crescence
- Aix Marseille Université, INSERM UMR-S1076, Vascular Research Center Marseille
| | - Christophe Dubois
- Aix Marseille Univ. (AMU), C2VN, 1263 INSERM, INRAE 1260, Marseille, France
| | | | | | | |
Collapse
|
2
|
Adam F, Chatellier G, Alfonsi P. Assessment of the concordance between DN4 scores performed by the patient (self-assessment) or by the physician (hetero-assessment) to detect subacute neuropathic postoperative pain. Eur J Pain 2024. [PMID: 38243671 DOI: 10.1002/ejp.2241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 12/26/2023] [Accepted: 01/06/2024] [Indexed: 01/21/2024]
Abstract
BACKGROUND Centres dedicated to chronic postsurgical pain (CPSP) have been developed, but delays for accessing to it are generally long. Teleconsultation might be a means to facilitate access to care by allowing an initial triage. CPSPs are neuropathic pain in around half of the cases and their diagnosis is mainly based on the score obtained from validated questionnaires. Among them, those requiring a neurological examination (i.e. the Douleur Neuropathique en 4 questions [DN4]) have a better sensitivity and specificity, and should be preferred. However, effectiveness of a remote neurological examination remains to be established. The aim of this observational study is to check during a face-to-face consultation if, after a short training, a naïve patient is capable to self-assess the clinical signs of neuropathic sensations. METHODS Thirty patients with suspected neuropathic pain were seen in a face-to-face postoperative pain consultation. Before examination, the patient was instructed to fill the DN4 questionnaire, including the neurological examination. Once explanations were given and checked, the patient was left and completed it alone. Then, the pain physician performed the DN4 questionnaire. Inter-rater reliability between patient and pain physician was assessed for each item and for DN4 score with the Kappa coefficient. RESULTS For each item of the DN4 questionnaire, Kappa coefficients were between 0.74 and 1, and could be considered as excellent. For DN4 ≥ 4, the Kappa coefficient was 0.86. CONCLUSIONS Our results suggest that after a short training, a naïve patient is capable of recognizing and diagnosing symptoms of neuropathic pain. SIGNIFICANCE Our results suggest that self-assessment, carried out after brief training and using a simple tool, provides results comparable to those obtained by a specialist physician to diagnose symptoms of neuropathic pain. If the results of the current study are confirmed on a larger scale, self-assessment will help improve access to specialized chronic pain care by better orienting patients and opening up access to teleconsultations.
Collapse
Affiliation(s)
- Frédéric Adam
- Department of Anesthesiology, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Gilles Chatellier
- Clinical Research Unit, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Pascal Alfonsi
- Department of Anesthesiology, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| |
Collapse
|
3
|
Kauskot A, Mallebranche C, Bruneel A, Fenaille F, Solarz J, Viellard T, Feng M, Repérant C, Bordet JC, Cholet S, Denis CV, McCluskey G, Latour S, Martin E, Pellier I, Lasne D, Borgel D, Kracker S, Ziegler A, Tuffigo M, Fournier B, Miot C, Adam F. MAGT1 deficiency in XMEN disease is associated with severe platelet dysfunction and impaired platelet glycoprotein N-glycosylation. J Thromb Haemost 2023; 21:3268-3278. [PMID: 37207862 DOI: 10.1016/j.jtha.2023.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 04/24/2023] [Accepted: 05/07/2023] [Indexed: 05/21/2023]
Abstract
BACKGROUND X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia (XMEN) disease is a primary immunodeficiency due to loss-of-function mutations in the gene encoding for magnesium transporter 1 (MAGT1). Furthermore, as MAGT1 is involved in the N-glycosylation process, XMEN disease is classified as a congenital disorder of glycosylation. Although XMEN-associated immunodeficiency is well described, the mechanisms underlying platelet dysfunction and those responsible for life-threatening bleeding events have never been investigated. OBJECTIVES To assess platelet functions in patients with XMEN disease. METHODS Two unrelated young boys, including one before and after hematopoietic stem cell transplantation, were investigated for their platelet functions, glycoprotein expression, and serum and platelet-derived N-glycans. RESULTS Platelet analysis highlighted abnormal elongated cells and unusual barbell-shaped proplatelets. Platelet aggregation, integrin αIIbβ3 activation, calcium mobilization, and protein kinase C activity were impaired between both patients. Strikingly, platelet responses to protease-activated receptor 1 activating peptide were absent at both low and high concentrations. These defects were also associated with decreased molecular weights of glycoprotein Ibα, glycoprotein VI, and integrin αIIb due to partial impairment of N-glycosylation. All these defects were corrected after hematopoietic stem cell transplantation. CONCLUSION Our results highlight prominent platelet dysfunction related to MAGT1 deficiency and defective N-glycosylation in several platelet proteins that could explain the hemorrhages reported in patients with XMEN disease.
Collapse
Affiliation(s)
- Alexandre Kauskot
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Coralie Mallebranche
- Université d'Angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT, Angers, France; CHU Angers, Pediatric immuno-hemato-oncology Unit, Angers, France
| | - Arnaud Bruneel
- AP-HP, Biochimie Métabolique et Cellulaire, Hôpital Bichat-Claude Bernard, Paris, France; Université Paris-Saclay, INSERM UMR1193, Mécanismes cellulaires et moléculaires de l'adaptation au stress et cancérogenèse, Châtenay-Malabry, France
| | - François Fenaille
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, MetaboHUB, Gif sur Yvette, France
| | - Jean Solarz
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Toscane Viellard
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Miao Feng
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Christelle Repérant
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Jean-Claude Bordet
- Laboratoire d'Hémostase, Centre de Biologie Est, Hospices Civils de Lyon, Bron, France
| | - Sophie Cholet
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, MetaboHUB, Gif sur Yvette, France
| | - Cécile V Denis
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Geneviève McCluskey
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Sylvain Latour
- INSERM UMR 1163, Laboratory of Lymphocyte Activation and Susceptibility to EBV, Imagine Institute, Université Paris Cité, Paris, France
| | - Emmanuel Martin
- INSERM UMR 1163, Laboratory of Lymphocyte Activation and Susceptibility to EBV, Imagine Institute, Université Paris Cité, Paris, France
| | - Isabelle Pellier
- Université d'Angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT, Angers, France; CHU Angers, Pediatric immuno-hemato-oncology Unit, Angers, France
| | - Dominique Lasne
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France; AP-HP, Laboratoire d'Hématologie, Hôpital Necker-Enfants Malades, Paris, France
| | - Delphine Borgel
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France; AP-HP, Laboratoire d'Hématologie, Hôpital Necker-Enfants Malades, Paris, France
| | - Sven Kracker
- INSERM UMR1163, Université Paris Cité, Laboratory of Human Lymphohematopoiesis, Imagine Institute, Paris, France
| | | | - Marie Tuffigo
- CHU Angers, Laboratory of Hematology, Angers, France
| | - Benjamin Fournier
- INSERM UMR 1163, Laboratory of Lymphocyte Activation and Susceptibility to EBV, Imagine Institute, Université Paris Cité, Paris, France; AP-HP, Hôpital Necker-Enfants Malades Assistance Publique-Hôpitaux de Paris, Pediatric Hematology-Immunology-Rheumatology Unit, Paris, France
| | - Charline Miot
- Université d'Angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT, Angers, France; CHU Angers, Pediatric immuno-hemato-oncology Unit, Angers, France; CHU Angers, Laboratory of Immunology and Allergology, Angers, France
| | - Frédéric Adam
- INSERM U1176, Hemostasis, Inflammation & Thrombosis (HITh), Université Paris-Saclay, Le Kremlin-Bicêtre, France.
| |
Collapse
|
4
|
Roullet S, Luc N, Rayes J, Solarz J, Disharoon D, Ditto A, Gahagan E, Pawlowski C, Sefiane T, Adam F, Casari C, Christophe OD, Bruckman M, Lenting PJ, Sen Gupta A, Denis CV. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models. Blood 2023; 141:2891-2900. [PMID: 36928925 PMCID: PMC10315625 DOI: 10.1182/blood.2022018956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 02/17/2023] [Accepted: 03/06/2023] [Indexed: 03/18/2023] Open
Abstract
The lack of innovation in von Willebrand disease (VWD) originates from many factors including the complexity and heterogeneity of the disease but also from a lack of recognition of the impact of the bleeding symptoms experienced by patients with VWD. Recently, a few research initiatives aiming to move past replacement therapies using plasma-derived or recombinant von Willebrand factor (VWF) concentrates have started to emerge. Here, we report an original approach using synthetic platelet (SP) nanoparticles for the treatment of VWD type 2B (VWD-2B) and severe VWD (type 3 VWD). SP are liposomal nanoparticles decorated with peptides enabling them to concomitantly bind to collagen, VWF, and activated platelets. In vitro, using various microfluidic assays, we show the efficacy of SPs to improve thrombus formation in VWF-deficient condition (with human platelets) or using blood from mice with VWD-2B and deficient VWF (VWF-KO, ie, type 3 VWD). In vivo, using a tail-clip assay, SP treatment reduced blood loss by 35% in mice with VWD-2B and 68% in mice with VWF-KO. Additional studies using nanoparticles decorated with various combinations of peptides demonstrated that the collagen-binding peptide, although not sufficient by itself, was crucial for SP efficacy in VWD-2B; whereas all 3 peptides appeared necessary for mice with VWF-KO. Clot imaging by immunofluorescence and scanning electron microscopy revealed that SP treatment of mice with VWF-KO led to a strong clot, similar to those obtained in wild-type mice. Altogether, our results show that SP could represent an attractive therapeutic alternative for VWD, especially considering their long half-life and stability.
Collapse
Affiliation(s)
- Stéphanie Roullet
- Laboratory for Hemostasis, Inflammation & Thrombosis, Unite Mixte de Recherche 1176 INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Norman Luc
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH
| | - Julie Rayes
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Jean Solarz
- Laboratory for Hemostasis, Inflammation & Thrombosis, Unite Mixte de Recherche 1176 INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Dante Disharoon
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH
| | | | | | | | - Thibaud Sefiane
- Laboratory for Hemostasis, Inflammation & Thrombosis, Unite Mixte de Recherche 1176 INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Frédéric Adam
- Laboratory for Hemostasis, Inflammation & Thrombosis, Unite Mixte de Recherche 1176 INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Caterina Casari
- Laboratory for Hemostasis, Inflammation & Thrombosis, Unite Mixte de Recherche 1176 INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Olivier D. Christophe
- Laboratory for Hemostasis, Inflammation & Thrombosis, Unite Mixte de Recherche 1176 INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | | | - Peter J. Lenting
- Laboratory for Hemostasis, Inflammation & Thrombosis, Unite Mixte de Recherche 1176 INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Anirban Sen Gupta
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH
| | - Cécile V. Denis
- Laboratory for Hemostasis, Inflammation & Thrombosis, Unite Mixte de Recherche 1176 INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| |
Collapse
|
5
|
Boussard C, Delage L, Gajardo T, Kauskot A, Batignes M, Goudin N, Stolzenberg MC, Brunaud C, Panikulam P, Riller Q, Moya-Nilges M, Solarz J, Repérant C, Durel B, Bordet JC, Pellé O, Lebreton C, Magérus A, Pirabakaran V, Vargas P, Dupichaud S, Jeanpierre M, Vinit A, Zarhrate M, Masson C, Aladjidi N, Arkwright PD, Bader-Meunier B, Baron Joly S, Benadiba J, Bernard E, Berrebi D, Bodemer C, Castelle M, Charbit-Henrion F, Chbihi M, Debray A, Drabent P, Fraitag S, Hié M, Landman-Parker J, Lhermitte L, Moshous D, Rohrlich P, Ruemmele F, Welfringer-Morin A, Tusseau M, Belot A, Cerf-Bensussan N, Roelens M, Picard C, Neven B, Fischer A, Callebaut I, Ménager M, Sepulveda FE, Adam F, Rieux-Laucat F. DOCK11 deficiency in patients with X-linked actinopathy and autoimmunity. Blood 2023; 141:2713-2726. [PMID: 36952639 DOI: 10.1182/blood.2022018486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 02/28/2023] [Accepted: 03/19/2023] [Indexed: 03/25/2023] Open
Abstract
Dedicator of cytokinesis (DOCK) proteins play a central role in actin cytoskeleton regulation. This is highlighted by the DOCK2 and DOCK8 deficiencies leading to actinopathies and immune deficiencies. DOCK8 and DOCK11 activate CDC42, a Rho-guanosine triphosphate hydrolases involved in actin cytoskeleton dynamics, among many cellular functions. The role of DOCK11 in human immune disease has been long suspected but, to the best of our knowledge, has never been described to date. We studied 8 male patients, from 7 unrelated families, with hemizygous DOCK11 missense variants leading to reduced DOCK11 expression. The patients were presenting with early-onset autoimmunity, including cytopenia, systemic lupus erythematosus, skin, and digestive manifestations. Patients' platelets exhibited abnormal ultrastructural morphology and spreading as well as impaired CDC42 activity. In vitro activated T cells and B-lymphoblastoid cell lines from patients exhibited aberrant protrusions and abnormal migration speed in confined channels concomitant with altered actin polymerization during migration. Knock down of DOCK11 recapitulated these abnormal cellular phenotypes in monocytes-derived dendritic cells and primary activated T cells from healthy controls. Lastly, in line with the patients' autoimmune manifestations, we also observed abnormal regulatory T-cell (Treg) phenotype with profoundly reduced FOXP3 and IKZF2 expression. Moreover, we found reduced T-cell proliferation and impaired STAT5B phosphorylation upon interleukin-2 stimulation of the patients' lymphocytes. In conclusion, DOCK11 deficiency is a new X-linked immune-related actinopathy leading to impaired CDC42 activity and STAT5 activation, and is associated with abnormal actin cytoskeleton remodeling as well as Treg phenotype, culminating in immune dysregulation and severe early-onset autoimmunity.
Collapse
Affiliation(s)
- Charlotte Boussard
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Laure Delage
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Tania Gajardo
- Université Paris Cité, Paris, France
- Laboratory of Molecular Basis of Altered Immune Homeostasis, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Alexandre Kauskot
- INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Maxime Batignes
- Université Paris Cité, Paris, France
- Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Institut Imagine, Atip-Avenir Team, INSERM UMR 1163, Paris, France
| | - Nicolas Goudin
- Université Paris Cité, Paris, France
- Necker Bio-image Analysis Platform, Structure Fédérative de Recherche Necker, INSERM US24, CNRS UMS3633, Paris, France
| | - Marie-Claude Stolzenberg
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Camille Brunaud
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Patricia Panikulam
- Université Paris Cité, Paris, France
- Laboratory of Molecular Basis of Altered Immune Homeostasis, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Quentin Riller
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | | | - Jean Solarz
- INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | | | - Béatrice Durel
- Université Paris Cité, Paris, France
- Cell Imaging Platform, Structure Fédérative de Recherche Necker, INSERM US24, CNRS UMS3633, Paris, France
| | - Jean-Claude Bordet
- Laboratoire d'Hémostase, Centre de Biologie Est, Hospices Civils de Lyon, Bron, France
| | - Olivier Pellé
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
- Flow Cytometry Core Facility, Structure Fédérative de Recherche Necker INSERM US24, CNRS UMS3633, Paris, France
| | - Corinne Lebreton
- Université Paris Cité, Paris, France
- Laboratory of Intestinal Immunity, Université Paris Cité, Imagine Institute, INSERM UMR-S_1163, Paris, France
| | - Aude Magérus
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Vithura Pirabakaran
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Pablo Vargas
- Université Paris Cité, Paris, France
- Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Université de Paris, Paris, France
| | | | - Marie Jeanpierre
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Angélique Vinit
- Sorbonne Université, UMS037, PASS, Plateforme de cytométrie de la Pitié-Salpêtrière CyPS, Paris, France
| | - Mohammed Zarhrate
- Université Paris Cité, Paris, France
- Genomics Core Facility, Institut Imagine-Structure Fédérative de Recherche Necker, INSERM U1163 et INSERM US24/CNRS UAR3633, Université Paris Cité, Paris, France
| | - Cécile Masson
- Université Paris Cité, Paris, France
- Bioinformatics Core Facility, Institut Imagine-Structure Fédérative de Recherche Necker, INSERM U1163 et INSERM US24/CNRS UAR3633, Université Paris Cité, Paris, France
| | - Nathalie Aladjidi
- Centre de Référence National des Cytopénies Auto-immunes de l'Enfant, Bordeaux, France
- Pediatric Oncology Hematology Unit, University Hospital, Plurithématique CIC, Centre d'Investigation Clinique, 1401, INSERM, Bordeaux, France
| | - Peter D Arkwright
- Lydia Becker Institute of Immunology and Inflammation, University of Manchester & Department of Pediatric Allergy and Immunology, Royal Manchester Children's Hospital, Manchester, United Kingdom
| | - Brigitte Bader-Meunier
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
- Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
- Reference Centre for Rheumatic, AutoImmune and Systemic Diseases in Children, Paris, France
| | | | - Joy Benadiba
- Department of Pediatric Hematology-Oncology, Nice University Hospital, Nice, France
| | - Elise Bernard
- Departement of General Pediatrics, Centre Hospitalier de Mayotte, Mamoudzou, France
| | - Dominique Berrebi
- Department of Pediatric Pathology, Hôpital Robert-Debré, Hôpital Universitaire Robert-Debré, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Christine Bodemer
- Université Paris Cité, Paris, France
- Department of Dermatology, Referral Center for Genodermatoses and Rare Skin Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
| | - Martin Castelle
- Université Paris Cité, Paris, France
- Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Fabienne Charbit-Henrion
- Laboratory of Intestinal Immunity, Université Paris Cité, Imagine Institute, INSERM UMR-S_1163, Paris, France
- Department of Pediatric Gastroenterology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
- Department of Genomic Medecine for Rare Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
- Department of Pediatric Nephrology, Rheumatology, Dermatology, Reference Centre for Rheumatic, AutoImmune and Systemic Diseases in Children, Hôpital Femme Mère Enfant, CHU Lyon, Bron, France
| | - Marwa Chbihi
- Université Paris Cité, Paris, France
- Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Agathe Debray
- Departement of General Pediatrics and Infectious Diseases, Hôpital Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Philippe Drabent
- Université Paris Cité, Paris, France
- Department of Anatomopathology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
| | - Sylvie Fraitag
- Université Paris Cité, Paris, France
- Department of Anatomopathology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
| | - Miguel Hié
- Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Service de Médecine Interne 2, Institut E3M, INSERM UMRS 1135, Centre d'Immunologie et des Maladies Infectieuses-Paris, Paris, France
| | - Judith Landman-Parker
- Sorbonne Université, Department of Pediatric Hematology Oncology, Hôpital Armand-Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Ludovic Lhermitte
- Université Paris Cité, Paris, France
- Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Institut Necker-Enfants Malades, INSERM UMR 1151, Paris, France
| | - Despina Moshous
- Université Paris Cité, Paris, France
- Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
- Laboratory of Genome Dynamics in the Immune System, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
- French National Reference Center for Primary Immune Deficiencies, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Pierre Rohrlich
- Department of Pediatric Hematology-Oncology, Nice University Hospital, Nice, France
| | - Frank Ruemmele
- Université Paris Cité, Paris, France
- Laboratory of Intestinal Immunity, Université Paris Cité, Imagine Institute, INSERM UMR-S_1163, Paris, France
- Department of Pediatric Gastroenterology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
| | - Anne Welfringer-Morin
- Université Paris Cité, Paris, France
- Department of Dermatology, Referral Center for Genodermatoses and Rare Skin Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
| | - Maud Tusseau
- Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France
| | - Alexandre Belot
- Centre International de Recherche en Infectiologie, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France
- Department of Pediatric Nephrology, Rheumatology, Dermatology, Reference Centre for Rheumatic, AutoImmune and Systemic Diseases in Children, Hôpital Femme Mère Enfant, CHU Lyon, Bron, France
| | - Nadine Cerf-Bensussan
- Université Paris Cité, Paris, France
- Laboratory of Intestinal Immunity, Université Paris Cité, Imagine Institute, INSERM UMR-S_1163, Paris, France
| | - Marie Roelens
- Université Paris Cité, Paris, France
- Study Center for Primary Immunodeficiencies, Hôpital Necker-Enfants Malades University, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Capucine Picard
- Université Paris Cité, Paris, France
- French National Reference Center for Primary Immune Deficiencies, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Study Center for Primary Immunodeficiencies, Hôpital Necker-Enfants Malades University, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Bénédicte Neven
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
- Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Alain Fischer
- Université Paris Cité, Paris, France
- Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
- Department of Pediatric Immuno-Haematology and Rheumatology, Reference Center for Rheumatic, AutoImmune and Systemic Diseases in Children, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
- Collège de France, Paris, France
| | - Isabelle Callebaut
- Sorbonne Université, Muséum National d'Histoire Naturelle, CNRS UMR 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Paris, France
| | - Mickaël Ménager
- Université Paris Cité, Paris, France
- Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Institut Imagine, Atip-Avenir Team, INSERM UMR 1163, Paris, France
- Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR-S_1163, Paris, France
| | - Fernando E Sepulveda
- Université Paris Cité, Paris, France
- Laboratory of Molecular Basis of Altered Immune Homeostasis, Institut Imagine, INSERM UMR-S_1163, Paris, France
| | - Frédéric Adam
- INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Frédéric Rieux-Laucat
- Université Paris Cité, Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, INSERM UMR-S_1163, Paris, France
| |
Collapse
|
6
|
McCarthy S, O'Raghallaigh P, Li Y, Adam F. Control enactment in context: Understanding the interaction of controlee and controller perceptions in inter‐organisational project teams. Information Systems Journal 2023. [DOI: 10.1111/isj.12434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
Affiliation(s)
- Stephen McCarthy
- Department of Business Information Systems, Cork University Business School University College Cork Cork Ireland
| | - Paidi O'Raghallaigh
- Department of Business Information Systems, Cork University Business School University College Cork Cork Ireland
| | - Yuzhu Li
- Department of Decision and Information Sciences University of Massachusetts Dartmouth Dartmouth Massachusetts USA
| | - Frédéric Adam
- Department of Business Information Systems, Cork University Business School University College Cork Cork Ireland
- INFANT SFI Centre University College Cork Cork Ireland
| |
Collapse
|
7
|
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, Hamdi-Chérif M, Kara L, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Ladipo A, Ogunbiyi OJ, Somdyala NIM, Chaplin MA, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Laspada WD, Ibañez SG, Lima CA, Da Costa AM, De Souza PCF, Chaves J, Laporte CA, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Almeida ABM, Latorre MRDO, Rebelo MS, Santos MO, Azevedo e Silva G, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Perez P, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Woods RR, Noonan G, Turner D, Kumar E, Zhang B, Dowden JJ, Doyle GP, Saint-Jacques N, Walsh G, Anam A, De P, McClure CA, Vriends KA, Bertrand C, Ramanakumar AV, Davis L, Kozie S, Freeman T, George JT, Avila RM, O’Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Ruterbusch J, Schwartz AG, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Davis J, Hernandez B, Johnson CJ, Morawski BM, Ruppert LP, Bentler S, Charlton ME, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Stern K, Gershman ST, Knowlton RC, Alverson G, Weaver T, Desai J, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Hammond W, Rees JR, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Dabbs C, Espinoza RE, Aird KG, Beran T, Rubertone JJ, Slack SJ, Oh J, Janes TA, Schwartz SM, Chiodini SC, Hurley DM, Whiteside MA, Rai S, Williams MA, Herget K, Sweeney C, Kachajian J, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Conaway JL, Borchers R, Malicki R, Espinoza J, Grandpre J, Weir HK, Wilson R, Edwards BK, Mariotto A, Rodriguez-Galindo C, Wang N, Yang L, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Chen WQ, Wei W, Zeng H, Demetriou AV, Mang WK, Ngan KC, Kataki AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, George PS, Mathew A, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Koyanagi Y, Sato M, Tobori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Mori D, Yoshitake M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Matsuda T, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Nansalmaa E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Lim GH, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajrang S, Suwanrungruang K, Vatanasapt P, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipaiboon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Eser S, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Atanasov TY, Valerianova Z, Šekerija M, Dušek L, Zvolský M, Steinrud Mørch L, Storm H, Wessel Skovlund C, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Dabakuyo Yonli S, Poillot ML, Maynadié M, Mounier M, Vaconnet L, Woronoff AS, Daoulas M, Robaszkiewicz M, Clavel J, Poulalhon C, Desandes E, Lacour B, Baldi I, Amadeo B, Coureau G, Monnereau A, Orazio S, Audoin M, D’Almeida TC, Boyer S, Hammas K, Trétarre B, Colonna M, Delafosse P, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Daubisse-Marliac L, Bossard N, Uhry Z, Estève J, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Justenhoven C, Reinwald F, Holleczek B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Murray DE, Walsh PM, Sundseth H, Harney M, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomin A, Magoni M, Ardizzone A, D’Argenzio A, Di Prima AA, Ippolito A, Lavecchia AM, Sutera Sardo A, Gola G, Ballotari P, Giacomazzi E, Ferretti S, Dal Maso L, Serraino D, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Andreano A, Russo AG, Carrozzi G, Cirilli C, Cavalieri d’Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Marguati S, Chiaranda G, Seghini P, Maule MM, Merletti F, Spata E, Tumino R, Mancuso P, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Piras D, Bella F, Madeddu A, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Rizzello R, Rosso S, Caldarella A, Intrieri T, Bianconi F, Contiero P, Tagliabue G, Rugge M, Zorzi M, Beggiato S, Brustolin A, Gatta G, De Angelis R, Vicentini M, Zanetti R, Stracci F, Maurina A, Oniščuka M, Mousavi M, Steponaviciene L, Vincerževskienė I, Azzopardi MJ, Calleja N, Siesling S, Visser O, Johannesen TB, Larønningen S, Trojanowski M, Macek P, Mierzwa T, Rachtan J, Rosińska A, Kępska K, Kościańska B, Barna K, Sulkowska U, Gebauer T, Łapińska JB, Wójcik-Tomaszewska J, Motnyk M, Patro A, Gos A, Sikorska K, Bielska-Lasota M, Didkowska JA, Wojciechowska U, Forjaz de Lacerda G, Rego RA, Carrito B, Pais A, Bento MJ, Rodrigues J, Lourenço A, Mayer-da-Silva A, Coza D, Todescu AI, Valkov MY, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova A, Orlov A, Pikalova LV, Zhuikova LD, Adamcik J, Safaei Diba C, Zadnik V, Žagar T, De-La-Cruz M, Lopez-de-Munain A, Aleman A, Rojas D, Chillarón RJ, Navarro AIM, Marcos-Gragera R, Puigdemont M, Rodríguez-Barranco M, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque López MD, Sánchez Gil A, Ardanaz E, Guevara M, Cañete-Nieto A, Peris-Bonet R, Carulla M, Galceran J, Almela F, Sabater C, Khan S, Pettersson D, Dickman P, Staehelin K, Struchen B, Egger Hayoz C, Rapiti E, Schaffar R, Went P, Mousavi SM, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolero A, Konzelmann I, Rohrmann S, Wanner M, Broggio J, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Morrison DS, Thomson CS, Greene G, Huws DW, Grayson M, Rawcliffe H, Allemani C, Coleman MP, Di Carlo V, Girardi F, Matz M, Minicozzi P, Sanz N, Ssenyonga N, James D, Stephens R, Chalker E, Smith M, Gugusheff J, You H, Qin Li S, Dugdale S, Moore J, Philpot S, Pfeiffer R, Thomas H, Silva Ragaini B, Venn AJ, Evans SM, Te Marvelde L, Savietto V, Trevithick R, Aitken J, Currow D, Fowler C, Lewis C. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25:580-592. [PMID: 36355361 PMCID: PMC10013649 DOI: 10.1093/neuonc/noac217] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
Collapse
Affiliation(s)
- Fabio Girardi
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.,Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Melissa Matz
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | - Charles Stiller
- National Cancer Registration and Analysis Service, Public Health England, London, UK
| | - Hui You
- Cancer Information Analysis Unit, Cancer Institute NSW, St Leonards, New South Wales, Australia
| | - Rafael Marcos Gragera
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Mikhail Y Valkov
- Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Arkhangelsk, Russia
| | - Jean-Luc Bulliard
- Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.,Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland
| | - Prithwish De
- Surveillance and Cancer Registry, and Research Office, Clinical Institutes and Quality Programs, Ontario Health, Toronto, Ontario, Canada
| | - David Morrison
- Scottish Cancer Registry, Public Health Scotland, Edinburgh, UK
| | - Miriam Wanner
- Cancer Registry Zürich, Zug, Schaffhausen and Schwyz, University Hospital Zürich, Zürich, Switzerland
| | - David K O'Brian
- Alaska Cancer Registry, Alaska Department of Health and Social Services, Anchorage, Alaska, USA
| | - Nathalie Saint-Jacques
- Department of Medicine and Community Health and Epidemiology, Centre for Clinical Research, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Michel P Coleman
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK
| | - Claudia Allemani
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Adam F, Jouët P, Sabaté JM, Perrot S, Franchisseur C, Attal N, Bouhassira D. Thermal grill illusion of pain in patients with chronic pain: a clinical marker of central sensitization? Pain 2023; 164:638-644. [PMID: 35972466 DOI: 10.1097/j.pain.0000000000002749] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 07/14/2022] [Indexed: 11/25/2022]
Abstract
ABSTRACT The thermal grill illusion of pain (TGIP) is a paradoxical burning pain sensation elicited by the simultaneous application of innocuous cutaneous warm and cold stimuli with a thermode ("thermal grill") consisting of interlaced heated and cooled bars. Its neurophysiological mechanisms are unclear, but TGIP may have some mechanisms in common with pathological pain, including central sensitization in particular, through the involvement of N-methyl- d -aspartate receptors. However, few studies have investigated TGIP in patients with chronic pain and its clinical relevance is uncertain. We hypothesized that the TGIP would be increased in comparison with controls in patients with fibromyalgia or irritable bowel syndrome, which are regarded as typical "nociplastic" primary pain syndromes related to changes in central pain processing. We compared the sensations elicited by a large range of combinations of temperature differentials between the warm and cold bars of a thermal grill applied to the hand between patients with fibromyalgia (n = 30) or irritable bowel syndrome (n= 30) and controls (n = 30). The percentage of TGIP responses and the intensity and unpleasantness of TGIP were significantly greater in patients than controls. Furthermore, positive correlations were found between TGIP intensity and clinical pain intensity and between TGIP intensity and the cold pain threshold measured on the hand. These results are consistent with our working hypothesis of shared mechanisms between TGIP and clinical pain mechanisms in patients with nociplastic chronic pain syndromes and suggest that TGIP might represent a clinical marker of central sensitization in these patients.
Collapse
Affiliation(s)
- Frédéric Adam
- Inserm U987, APHP, UVSQ, Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France
- Department of Anesthesiology, Saint Joseph Hospital, Paris, France
| | - Pauline Jouët
- Inserm U987, APHP, UVSQ, Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France
- Gastroenterology and Digestive Oncology Department, Avicenne Hospital, AP-HP, Bobigny, France
| | - Jean-Marc Sabaté
- Inserm U987, APHP, UVSQ, Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France
- Gastroenterology and Digestive Oncology Department, Avicenne Hospital, AP-HP, Bobigny, France
| | - Serge Perrot
- Inserm U987, APHP, UVSQ, Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France
- Pain Clinic, Cochin Hospital, University of Paris, Paris, France
| | - Claire Franchisseur
- Inserm U987, APHP, UVSQ, Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France
| | - Nadine Attal
- Inserm U987, APHP, UVSQ, Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France
| | - Didier Bouhassira
- Inserm U987, APHP, UVSQ, Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France
| |
Collapse
|
9
|
Feng M, Hechler B, Adam F, Gachet C, Eckly A, Kauskot A, Denis CV, Bryckaert M, Bobe R, Rosa JP. ADP receptor P2Y12 is the capstone of the cross-talk between Ca2+ mobilization pathways dependent on Ca2+ ATPases sarcoplasmic/endoplasmic reticulum type 3 and type 2b in platelets. Res Pract Thromb Haemost 2022; 7:100004. [PMID: 36970741 PMCID: PMC10031336 DOI: 10.1016/j.rpth.2022.100004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 11/10/2022] [Accepted: 11/14/2022] [Indexed: 01/07/2023] Open
Abstract
Background Blood platelet Ca2+ stores are regulated by 2 Ca2+-ATPases (SERCA2b and SERCA3). On thrombin stimulation, nicotinic acid adenosine dinucleotide phosphate mobilizes SERCA3-dependent stores, inducing early adenosine 5'-diphosphate (ADP) secretion, potentiating later SERCA2b-dependent secretion. Objectives The aim of this study was to identify which ADP P2 purinergic receptor (P2Y1 and/or P2Y12) is(are) involved in the amplification of platelet secretion dependent on the SERCA3-dependent Ca2+ mobilization pathway (SERCA3 stores mobilization) as triggered by low concentration of thrombin. Methods The study used the pharmacologic antagonists MRS2719 and AR-C69931MX, of the P2Y1 and P2Y12, respectively, as well as Serca3 -/- mice and mice exhibiting platelet lineage-specific inactivation of the P2Y1 or P2Y12 genes. Results We found that in mouse platelets, pharmacological blockade or gene inactivation of P2Y12 but not of P2Y1 led to a marked inhibition of ADP secretion after platelet stimulation with low concentration of thrombin. Likewise, in human platelets, pharmacological inhibition of P2Y12 but not of P2Y1 alters amplification of thrombin-elicited secretion through SERCA2b stores mobilization. Finally, we show that early SERCA3 stores secretion of ADP is a dense granule secretion, based on parallel adenosine triphosphate and serotonin early secretion. Furthermore, early secretion involves a single granule, based on the amount of adenosine triphosphate released. Conclusion Altogether, these results show that at low concentrations of thrombin, SERCA3- and SERCA2b-dependent Ca2+ mobilization pathways cross-talk via ADP and activation of the P2Y12, and not the P2Y1 ADP receptor. The relevance in hemostasis of the coupling of the SERCA3 and the SERCA2b pathways is reviewed.
Collapse
|
10
|
Adam F, Kauskot A, Lamrani L, Solarz J, Soukaseum C, Repérant C, Denis CV, Raslova H, Rosa J, Bryckaert M. A gain-of-function filamin A mutation in mouse platelets induces thrombus instability. J Thromb Haemost 2022; 20:2666-2678. [PMID: 36006037 PMCID: PMC9826440 DOI: 10.1111/jth.15864] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 08/19/2022] [Accepted: 08/22/2022] [Indexed: 01/11/2023]
Abstract
BACKGROUND Filaminopathies A are rare disorders affecting the brain, intestine, or skeleton, characterized by dominant X-linked filamin A (FLNA) gene mutations. Macrothrombocytopenia with functionally defective platelets is frequent. We have described a filaminopathy A male patient, exhibiting a C-terminal frame-shift FLNa mutation (Berrou et al., Arterioscler Thromb Vasc Biol. 2017;37:1087-1097). Contrasting with female patients, this male patient exhibited gain of platelet functions, including increased platelet aggregation, integrin αIIbβ3 activation, and secretion at low agonist concentration, raising the issue of thrombosis risk. OBJECTIVES Our goal is to assess the thrombotic potential of the patient FLNa mutation in an in vivo model. METHODS We have established a mutant FlnA knock-in mouse model. RESULTS The mutant FlnA mouse platelets phenocopied patient platelets, showing normal platelet count, lower expression level of mutant FlnA, and gain of platelet functions: increased platelet aggregation, secretion, and αIIbβ3 activation, as well as increased spreading and clot retraction. Surprisingly, mutant FlnA mice exhibited a normal bleeding time, but with increased re-bleeding (77%) compared to wild type (WT) FlnA mice (27%), reflecting hemostatic plug instability. Again, in an in vivo thrombosis model, the occlusion time was not altered by the FlnA mutation, but arteriolar embolies were increased (7-fold more frequent in mutant FlnA mice versus WT mice), confirming thrombus instability. CONCLUSIONS This study shows that the FlnA mutation found in the male patient induced gain of platelet functions in vitro, but thrombus instability in vivo. Implications for the role of FLNa in physiology of thrombus formation are discussed.
Collapse
Affiliation(s)
- Frédéric Adam
- INSERM UMR_S 1176, HIThUniversité Paris‐SaclayLe Kremlin BicêtreFrance
| | - Alexandre Kauskot
- INSERM UMR_S 1176, HIThUniversité Paris‐SaclayLe Kremlin BicêtreFrance
| | - Lamia Lamrani
- INSERM UMR_S 1176, HIThUniversité Paris‐SaclayLe Kremlin BicêtreFrance
| | - Jean Solarz
- INSERM UMR_S 1176, HIThUniversité Paris‐SaclayLe Kremlin BicêtreFrance
| | | | | | - Cécile V. Denis
- INSERM UMR_S 1176, HIThUniversité Paris‐SaclayLe Kremlin BicêtreFrance
| | - Hana Raslova
- INSERM UMR 1287, Institut National de la Santé et de la Recherche Médicale, Université Paris‐Saclay, Gustave Roussy Cancer CampusEquipe Labellisée Ligue Nationale Contre le CancerVillejuifFrance
| | | | - Marijke Bryckaert
- INSERM UMR_S 1176, HIThUniversité Paris‐SaclayLe Kremlin BicêtreFrance
| |
Collapse
|
11
|
Mat Yasin NH, Othman NA, Adam F. Evaluation of the properties on carrageenan bio-films with Chlorella vulgaris blending. CHEM ENG COMMUN 2022. [DOI: 10.1080/00986445.2022.2103684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- N. H. Mat Yasin
- Faculty of Chemical & Process Engineering Technology, Universiti Malaysia Pahang, Gambang, Pahang, Malaysia
| | - N. A. Othman
- Faculty of Chemical & Process Engineering Technology, Universiti Malaysia Pahang, Gambang, Pahang, Malaysia
| | - F. Adam
- Faculty of Chemical & Process Engineering Technology, Universiti Malaysia Pahang, Gambang, Pahang, Malaysia
- Centre of Excellence for Advanced Research in Fluid Flow (CARIFF), Universiti Malaysia Pahang, Gambang, Pahang, Malaysia
| |
Collapse
|
12
|
d'Ussel M, Adam F, Fels A, Chatellier G, Philippart F. Characteristics of Hospital Workers Using a Wellbeing Center Implemented During the COVID-19 Pandemic to Prevent the Emotional Impacts of the Crisis. Front Public Health 2022; 10:913126. [PMID: 35859769 PMCID: PMC9289445 DOI: 10.3389/fpubh.2022.913126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Accepted: 06/08/2022] [Indexed: 11/13/2022] Open
Abstract
IntroductionThe COVID-19 pandemic has posed an unprecedented challenge worldwide for healthcare workers (HCWs) and other hospital employees. Disruptions in work and personal life may have led to mental health problems. To prevent or limit the severity of such issues, a local initiative has been implemented in a French hospital: a dedicated lounge, also called “Bulle” (literally bubble and meaning safe space) has been created to provide a quiet caring environment and health support. Other similar wellbeing centers have been implemented in other countries, but very little data are available on their practical effectiveness. The purpose of our study was to assess what type of hospital workers have frequented the Bulle and to describe their psychological state in terms of anxiety, depression, and post-traumatic stress disorder (PTSD) just after the first wave, compared to those who had not come to the Bulle.MethodsFrom 15 July to 1 October 2020, a cross-sectional survey was conducted among all workers, collecting demographic information, professional data (experience and satisfaction), emotional experience during the first wave of COVID-19, and psychological specificities, including a history of burnout or symptoms of anxiety, depression, and PTSD. We asked them if they had accessed the Bulle or not.ResultsA total of 675 employees (out of 2,408; 28.0%) fully completed the survey. Approximately 199 respondents (29%) reported having accessed the Bulle during the first wave of the pandemic. Significant symptoms of anxiety, depression, and PTSD were reported by, respectively, 41, 20, and 14% of the participants. Logistic regression analysis showed no relationship between the use of the Bulle and the prevalence of later psychological symptoms. However, employees who benefit from the solicitation of the psychological support team in their hospital unit were secondarily more prone to come to the Bulle [odds ratio (OR), 2.24; 95% confidence interval (95% CI): 1.09; 4.59].ConclusionAnxiety, depression, and PTSD were common after the first part of the COVID-19 pandemic, and the attendance in quiet and wellbeing spaces seemed easier with direct internal proactive intervention by psychological teams.
Collapse
Affiliation(s)
- Marguerite d'Ussel
- Chronic Pain Unit, Groupe Hospitalier Paris Saint-Joseph, Paris, France
- *Correspondence: Marguerite d'Ussel
| | - Frédéric Adam
- Department of Anesthesia, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Audrey Fels
- Clinical Research Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Gilles Chatellier
- Clinical Research Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France
- Université Paris Cité, Paris, France
| | - François Philippart
- Department of Intensive Care Medicine and Reanimation, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| |
Collapse
|
13
|
Sedzro JC, Adam F, Auditeau C, Bianchini E, De Carvalho A, Peyron I, Daramé S, Gandrille S, Thomassen S, Hackeng TM, Christophe OD, Lenting PJ, Denis CV, Borgel D, Saller F. Antithrombotic potential of a single-domain antibody enhancing the activated protein C-cofactor activity of protein S. J Thromb Haemost 2022; 20:1653-1664. [PMID: 35445541 DOI: 10.1111/jth.15736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 04/05/2022] [Accepted: 04/19/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND Protein S (PS) is a natural anticoagulant acting as a cofactor for activated protein C (APC) in the proteolytic inactivation of activated factors V (FVa) and VIII (FVIIIa), but also for tissue factor pathway inhibitor α (TFPIα) in the inhibition of activated factor X (FXa). OBJECTIVE For therapeutic purposes, we aimed at generating single-domain antibodies (sdAbs) that could specifically modulate the APC-cofactor activity of PS in vivo. METHODS A llama-derived immune library of sdAbs was generated and screened on recombinant human PS by phage display. PS binders were tested in a global activated partial thromboplastin time (APTT)-based APC-cofactor activity assay. RESULTS A PS-specific sdAb (PS003) was found to enhance the APC-cofactor activity of PS in our APTT-based assay, and this enhancing effect was greater for a bivalent form of PS003 (PS003biv). Further characterization of PS003biv demonstrated that PS003biv also enhanced the APC-cofactor activity of PS in a tissue factor (TF)-induced thrombin generation assay and stimulated APC in the inactivation of FVa, but not FVIIIa, in plasma-based assays. Furthermore, PS003biv was directed against the sex hormone-binding globulin (SHBG)-like domain but did not inhibit the binding of PS to C4b-binding protein (C4BP) and did not interfere with the TFPIα-cofactor activity of PS. In mice, PS003biv exerted an antithrombotic effect in a FeCl3 -induced thrombosis model, while not affecting physiological hemostasis in a tail-clip bleeding model. DISCUSSION Altogether, these results showed that pharmacological enhancement of the APC-cofactor activity of PS through an original anti-PS sdAb might constitute a promising and safe antithrombotic strategy.
Collapse
Affiliation(s)
- Josepha C Sedzro
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Frédéric Adam
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Claire Auditeau
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
- Service d'Hématologie Biologique, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Elsa Bianchini
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Allan De Carvalho
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Ivan Peyron
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Sadyo Daramé
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Sophie Gandrille
- Innovations Thérapeutiques en Hémostase, UMR-S1140, INSERM, Université de Paris, Paris, France
- Service d'Hématologie Biologique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Stella Thomassen
- Cardiovascular Research Institute Maastricht (CARIM), University Maastricht, Maastricht, the Netherlands
| | - Tilman M Hackeng
- Cardiovascular Research Institute Maastricht (CARIM), University Maastricht, Maastricht, the Netherlands
| | - Olivier D Christophe
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Peter J Lenting
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Cécile V Denis
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Delphine Borgel
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
- Service d'Hématologie Biologique, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - François Saller
- Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| |
Collapse
|
14
|
d’Ussel M, Fels A, Durand X, Lemogne C, Chatellier G, Castreau N, Adam F. Factors associated with psychological symptoms in hospital workers of a French hospital during the COVID-19 pandemic: Lessons from the first wave. PLoS One 2022; 17:e0267032. [PMID: 35482772 PMCID: PMC9049512 DOI: 10.1371/journal.pone.0267032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 03/31/2022] [Indexed: 01/30/2023] Open
Abstract
Purpose The COVID-19 pandemic has put hospital workers around the world in an unprecedented and difficult situation, possibly leading to emotional difficulties and mental health problems. We aimed to analyze psychological symptoms of the hospital employees of the Paris Saint-Joseph Hospital Group a few months after the 1st wave of the pandemic. Participants and methods From July 15 to October 1, 2020, a cross-sectional survey was conducted among hospital workers in the two locations of our hospital group using the Hospital Anxiety and Depression Scale (HADS) and Post-Traumatic Stress Disorder (PTSD) Checklist (PCL) to measure anxiety, depression, and PTSD symptoms. Factors independently associated with these symptoms were identified. Results In total, 780 participants (47% caregivers, 18% health administrative workers, 16% physicians, and 19% other professionals) completed the survey. Significant symptoms of anxiety, depression, and PTSD were reported by 41%, 21%, and 14% of the participants, respectively. Hierarchical regression analysis showed a higher risk of having psychological symptoms among those (1) who were infected by SARS-CoV-2 or had colleagues or relatives infected by the virus, (2) who retrospectively reported to have had an anxious experience during the first wave, and (3) with a previous history of burnout or depression. In contrast, job satisfaction appeared to be a protective factor. Overall, hospital workers showed the statistically same levels of anxiety, depression, and PTSD symptoms, regardless of their profession and whether they had worked in units with COVID-19 patients or not. Conclusions Our cross-sectional survey of 780 hospital workers shows that after the first wave, hospital employees had a significant burden of mental health symptoms. Specific preventive measures to promote mental well-being among hospital workers exposed to COVID-19 need to be implemented, first among particularly vulnerable staff, and then, for all hospital staff for whom anxiety is detected early, and not only those who were directly exposed to infected patients.
Collapse
Affiliation(s)
- M. d’Ussel
- Consultation Douleur Chronique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
- * E-mail:
| | - A. Fels
- Centre de Recherche Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - X. Durand
- Service de Chirurgie Urologique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - C. Lemogne
- AP-HP, Hôpital Hôtel-Dieu, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l’Adulte, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Université de Paris, Paris, France
| | - G. Chatellier
- Département de Recherche Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - N. Castreau
- Service de Santé au Travail, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - F. Adam
- Département d’Anesthésie, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| |
Collapse
|
15
|
Lamrani L, Adam F, Soukaseum C, Denis CV, Raslova H, Rosa J, Bryckaert M. New insights into regulation of αIIbβ3 integrin signaling by filamin A. Res Pract Thromb Haemost 2022; 6:e12672. [PMID: 35316942 PMCID: PMC8924993 DOI: 10.1002/rth2.12672] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 12/29/2021] [Accepted: 01/05/2022] [Indexed: 12/14/2022] Open
Abstract
Background Filamin (FLN) regulates many cell functions through its scaffolding activity cross‐linking cytoskeleton and integrins. FLN was shown to inhibit integrin activity, but the exact mechanism remains unclear. Objectives The aim of this study was to evaluate the role of filamin A (FLNa) subdomains on the regulation of integrin αIIbβ3 signaling. Methods Three FLNa deletion mutants were overexpressed in the erythro‐megakaryocytic leukemic cell line HEL: Del1, which lacks the N‐terminal CH1‐CH2 domains mediating the FLNa‐actin interaction; Del2, lacking the Ig‐like repeat 21, which mediates the FLNa‐β3 interaction; and Del3, lacking the C‐terminal Ig repeat 24, responsible for FLNa dimerization and interaction with the small Rho guanosine triphosphatase involved in actin cytoskeleton reorganisation. Fibrinogen binding to HEL cells in suspension and talin‐β3 proximity in cells adherent to immobilized fibrinogen were assessed before and after αIIbβ3 activation by the protein kinase C agonist phorbol 12‐myristate 13‐acetate. Results Our results show that FLNa‐actin and FLNa‐β3 interactions negatively regulate αIIbβ3 activation. Moreover, FLNa‐actin interaction represses Rac activation, contributing to the negative regulation of αIIbβ3 activation. In contrast, the FLNa dimerization domain, which maintains Rho inactive, was found to negatively regulate αIIbβ3 outside‐in signaling. Conclusion We conclude that FLNa negatively controls αIIbβ3 activation by regulating actin polymerization and restraining activation of Rac, as well as outside‐in signaling by repressing Rho.
Collapse
Affiliation(s)
- Lamia Lamrani
- HITh UMR_S1176 Institut National de la Santé et de la Recherche Médicale Université Paris‐Saclay Le Kremlin‐Bicêtre France
| | - Frédéric Adam
- HITh UMR_S1176 Institut National de la Santé et de la Recherche Médicale Université Paris‐Saclay Le Kremlin‐Bicêtre France
| | - Christelle Soukaseum
- HITh UMR_S1176 Institut National de la Santé et de la Recherche Médicale Université Paris‐Saclay Le Kremlin‐Bicêtre France
| | - Cécile V. Denis
- HITh UMR_S1176 Institut National de la Santé et de la Recherche Médicale Université Paris‐Saclay Le Kremlin‐Bicêtre France
| | - Hana Raslova
- UMR_S1170 Institut National de la Santé et de la Recherche Médicale Université Paris‐Sud Université Paris‐Saclay Gustave Roussy Cancer Campus Equipe Labellisée Ligue Nationale Contre le Cancer Villejuif France
| | - Jean‐Philippe Rosa
- HITh UMR_S1176 Institut National de la Santé et de la Recherche Médicale Université Paris‐Saclay Le Kremlin‐Bicêtre France
| | - Marijke Bryckaert
- HITh UMR_S1176 Institut National de la Santé et de la Recherche Médicale Université Paris‐Saclay Le Kremlin‐Bicêtre France
| |
Collapse
|
16
|
Adam F, Potet A. Pleine conscience et satisfaction conjugale : étude auprès de femmes en couple. Sexologies 2022. [DOI: 10.1016/j.sexol.2021.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
McCarthy S, O'Raghallaigh P, Fitzgerald C, Adam F. Shared and fragmented understandings in interorganizational IT project teams: An interpretive case study. International Journal of Project Management 2021. [DOI: 10.1016/j.ijproman.2021.07.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
18
|
Razanakolona M, Adam F, Bianchini E, Saller F, Carvalho AD, Diehl JL, Denis CV, Meziani F, Borgel D, Helms J, Vasse M. Anti-inflammatory Activity of the Protein Z-Dependent Protease Inhibitor. TH Open 2021; 5:e220-e229. [PMID: 34189397 PMCID: PMC8233056 DOI: 10.1055/s-0041-1730037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 04/08/2021] [Indexed: 12/19/2022] Open
Abstract
The protein Z (PZ)-dependent plasma protease inhibitor (ZPI) is a glycoprotein that inhibits factor XIa and, in the presence of PZ, FXa. Recently, ZPI has been shown to be an acute-phase protein (APP). As usually APPs downregulate the harmful effects of inflammation, we tested whether ZPI could modulate the increase of cytokines observed in inflammatory states. We observed that recombinant human ZPI (rhZPI) significantly decreases the levels of interleukin (IL)-1, IL-6, and tumor necrosis factor- α (TNF-α) induced by lipopolysaccharide (LPS) in a whole blood model. This inhibitory effect was unaffected by the presence of PZ or heparin. A ZPI mutant within the reactive loop center ZPI (Y387A), lacking anticoagulant activity, still had an anti-inflammatory activity. Surprisingly, rhZPI did not inhibit the synthesis of IL-6 or TNF-α when purified monocytes were stimulated by LPS, whereas the inhibitory effect was evidenced when lymphocytes were added to monocytes. The requirement of lymphocytes could be due to the synthesis of CCL5 (RANTES), a chemokine mainly produced by activated lymphocytes which is induced by rhZPI, and which can reduce the production of proinflammatory cytokines in whole blood. Lastly, we observed that the intraperitoneal injection of rhZPI significantly decreased LPS-induced IL-6 and TNF-α production in mouse plasma.
Collapse
Affiliation(s)
- Mahita Razanakolona
- HITh, INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre cedex, France
| | - Frédéric Adam
- HITh, INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre cedex, France
| | - Elsa Bianchini
- HITh, INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre cedex, France
| | - François Saller
- HITh, INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre cedex, France
| | - Allan de Carvalho
- HITh, INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre cedex, France
| | - Jean-Luc Diehl
- Département de réanimation médicale, Hôpital Européen Georges Pompidou, Paris, France
| | - Cécile V Denis
- HITh, INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre cedex, France
| | - Ferhat Meziani
- Faculté de Médecine, Service de Médecine Intensive-Réanimation, Université de Strasbourg (UNISTRA), Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France.,INSERM (French National Institute of Health and Medical Research), Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France
| | - Delphine Borgel
- HITh, INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre cedex, France.,APHP, Laboratoire d'Hématologie, Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | - Julie Helms
- Faculté de Médecine, Service de Médecine Intensive-Réanimation, Université de Strasbourg (UNISTRA), Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France.,ImmunoRhumatologie Moléculaire, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - Marc Vasse
- HITh, INSERM, UMR_S1176, Université Paris-Saclay, Le Kremlin-Bicêtre cedex, France.,Service de Biologie Clinique, Hôpital Foch, Suresnes, France
| |
Collapse
|
19
|
Verna E, Costedoat C, Stevanovitch A, Adam F, Desfossés Y, Jacques A, Signoli M. French soldiers who died during both World Wars: from recovery to repatriation. Forensic Sci Int 2020; 316:110484. [DOI: 10.1016/j.forsciint.2020.110484] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 08/28/2020] [Accepted: 08/29/2020] [Indexed: 10/23/2022]
|
20
|
McCarthy S, O'Raghallaigh P, Woodworth S, Lim YY, Kenny LC, Adam F. Embedding the Pillars of Quality in Health Information Technology Solutions Using "Integrated Patient Journey Mapping" (IPJM): Case Study. JMIR Hum Factors 2020; 7:e17416. [PMID: 32940610 PMCID: PMC7530692 DOI: 10.2196/17416] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Revised: 05/08/2020] [Accepted: 05/26/2020] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Health information technology (HIT) and associated data analytics offer significant opportunities for tackling some of the more complex challenges currently facing the health care sector. However, to deliver robust health care service improvements, it is essential that HIT solutions be designed by parallelly considering the 3 core pillars of health care quality: clinical effectiveness, patient safety, and patient experience. This requires multidisciplinary teams to design interventions that both adhere to medical protocols and achieve the tripartite goals of effectiveness, safety, and experience. OBJECTIVE In this paper, we present a design tool called Integrated Patient Journey Mapping (IPJM) that was developed to assist multidisciplinary teams in designing effective HIT solutions to address the 3 core pillars of health care quality. IPJM is intended to support the analysis of requirements as well as to promote empathy and the emergence of shared commitment and understanding among multidisciplinary teams. METHODS A 6-month, in-depth case study was conducted to derive findings on the use of IPJM during Learning to Evaluate Blood Pressure at Home (LEANBH), a connected health project that developed an HIT solution for the perinatal health context. Data were collected from over 700 hours of participant observations and 10 semistructured interviews. RESULTS The findings indicate that IPJM offered a constructive tool for multidisciplinary teams to work together in designing an HIT solution, through mapping the physical and emotional journey of patients for both the current service and the proposed connected health service. This allowed team members to consider the goals, tasks, constraints, and actors involved in the delivery of this journey and to capture requirements for the digital touchpoints of the connected health service. CONCLUSIONS Overall, IPJM facilitates the design and implementation of complex HITs that require multidisciplinary participation.
Collapse
Affiliation(s)
- Stephen McCarthy
- Department of Business Information Systems, Cork University Business School, University College Cork, Cork, Ireland
| | - Paidi O'Raghallaigh
- Department of Business Information Systems, Cork University Business School, University College Cork, Cork, Ireland
| | - Simon Woodworth
- Department of Business Information Systems, Cork University Business School, University College Cork, Cork, Ireland
| | - Yoke Yin Lim
- Cork University Maternity Hospital, Cork, Ireland
| | - Louise C Kenny
- Dept. of Women's and Children's Health, Institute of Life Course & Medical Sciences, University of Liverpool, Liverpool, United Kingdom
| | - Frédéric Adam
- Department of Business Information Systems, Cork University Business School, University College Cork, Cork, Ireland.,INFANT SFI Centre, University College Cork, Cork, Ireland
| |
Collapse
|
21
|
Feng M, Elaïb Z, Borgel D, Denis CV, Adam F, Bryckaert M, Rosa JP, Bobe R. NAADP/SERCA3-Dependent Ca 2+ Stores Pathway Specifically Controls Early Autocrine ADP Secretion Potentiating Platelet Activation. Circ Res 2020; 127:e166-e183. [PMID: 32588751 DOI: 10.1161/circresaha.119.316090] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
RATIONALE Ca2+ signaling is a key and ubiquitous actor of cell organization and its modulation controls many cellular responses. SERCAs (sarco-endoplasmic reticulum Ca2+-ATPases) pump Ca2+ into internal stores that play a major role in the cytosolic Ca2+ concentration rise upon cell activation. Platelets exhibit 2 types of SERCAs, SERCA2b and SERCA3 (SERCA3 deficient mice), which may exert specific roles, yet ill-defined. We have recently shown that Ca2+ mobilization from SERCA3-dependent stores was required for full platelet activation in weak stimulation conditions. OBJECTIVE To uncover the signaling mechanisms associated with Ca2+ mobilization from SERCA3-dependent stores leading to ADP secretion. METHODS AND RESULTS Using platelets from wild-type or Serca3-deficient mice, we demonstrated that an early (within 5-10 s following stimulation) secretion of ADP specifically dependent on SERCA3 stored Ca2+ is exclusively mobilized by nicotinic acid adenosine dinucleotide-phosphate (NAADP): both Ca2+ mobilization from SERCA3-dependent stores and primary ADP secretion are blocked by the NAADP receptor antagonist Ned-19, and reciprocally both are stimulated by permeant NAADP. In contrast, Ca2+ mobilization from SERCA3-dependent stores and primary ADP secretion were unaffected by inhibition of the production of IP3 (inositol-1,4,5-trisphosphate) by phospholipase-C and accordingly were not stimulated by permeant IP3. CONCLUSIONS Upon activation, an NAADP/SERCA3 Ca2+ mobilization pathway initiates an early ADP secretion, potentiating platelet activation, and a secondary wave of ADP secretion driven by both an IP3/SERCA2b-dependent Ca2+ stores pathway and the NAADP/SERCA3 pathway. This does not exclude that Ca2+ mobilized from SERCA3 stores may also enhance platelet global reactivity to agonists. Because of its modulating effect on platelet activation, this NAADP-SERCA3 pathway may be a relevant target for anti-thrombotic therapy. Graphic Abstract: A graphic abstract is available for this article.
Collapse
Affiliation(s)
- Miao Feng
- From the HITh, UMR_S1176, INSERM, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Ziane Elaïb
- From the HITh, UMR_S1176, INSERM, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Delphine Borgel
- From the HITh, UMR_S1176, INSERM, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Cécile V Denis
- From the HITh, UMR_S1176, INSERM, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Frédéric Adam
- From the HITh, UMR_S1176, INSERM, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Marijke Bryckaert
- From the HITh, UMR_S1176, INSERM, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Jean-Philippe Rosa
- From the HITh, UMR_S1176, INSERM, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Régis Bobe
- From the HITh, UMR_S1176, INSERM, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| |
Collapse
|
22
|
Adam F, Day J, De Sutter P, Brasseur C. L’utilisation de la pleine conscience dans le traitement du trouble de l’orgasme féminin. Sexologies 2019. [DOI: 10.1016/j.sexol.2019.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
Stoupa A, Adam F, Kariyawasam D, Strassel C, Gawade S, Szinnai G, Kauskot A, Lasne D, Janke C, Natarajan K, Schmitt A, Bole-Feysot C, Nitschke P, Léger J, Jabot-Hanin F, Tores F, Michel A, Munnich A, Besmond C, Scharfmann R, Lanza F, Borgel D, Polak M, Carré A. TUBB1 mutations cause thyroid dysgenesis associated with abnormal platelet physiology. EMBO Mol Med 2019; 10:emmm.201809569. [PMID: 30446499 PMCID: PMC6284387 DOI: 10.15252/emmm.201809569] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The genetic causes of congenital hypothyroidism due to thyroid dysgenesis (TD) remain largely unknown. We identified three novel TUBB1 gene mutations that co‐segregated with TD in three distinct families leading to 1.1% of TUBB1 mutations in TD study cohort. TUBB1 (Tubulin, Beta 1 Class VI) encodes for a member of the β‐tubulin protein family. TUBB1 gene is expressed in the developing and adult thyroid in humans and mice. All three TUBB1 mutations lead to non‐functional α/β‐tubulin dimers that cannot be incorporated into microtubules. In mice, Tubb1 knock‐out disrupted microtubule integrity by preventing β1‐tubulin incorporation and impaired thyroid migration and thyroid hormone secretion. In addition, TUBB1 mutations caused the formation of macroplatelets and hyperaggregation of human platelets after stimulation by low doses of agonists. Our data highlight unexpected roles for β1‐tubulin in thyroid development and in platelet physiology. Finally, these findings expand the spectrum of the rare paediatric diseases related to mutations in tubulin‐coding genes and provide new insights into the genetic background and mechanisms involved in congenital hypothyroidism and thyroid dysgenesis.
Collapse
Affiliation(s)
- Athanasia Stoupa
- INSERM U1016, Faculté de Médecine, Cochin Institute, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,IMAGINE Institute Affiliate, Paris, France.,RARE Disorder Center: Centre des Maladies Endocriniennes Rares de la Croissance et du Développement, Paris, France.,Pediatric Endocrinology, Gynecology and Diabetology Unit, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - Frédéric Adam
- INSERM UMR_S1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Dulanjalee Kariyawasam
- RARE Disorder Center: Centre des Maladies Endocriniennes Rares de la Croissance et du Développement, Paris, France.,Pediatric Endocrinology, Gynecology and Diabetology Unit, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - Catherine Strassel
- INSERM, EFS Grand Est, BPPS UMR-S 1255, FMTS, Université de Strasbourg, Strasbourg, France
| | - Sanjay Gawade
- Department of Biomedicine, Pediatric Immunology, University of Basel, Basel, Switzerland
| | - Gabor Szinnai
- Department of Biomedicine, Pediatric Immunology, University of Basel, Basel, Switzerland.,Pediatric Endocrinology, University Children's Hospital Basel, University of Basel, Basel, Switzerland
| | - Alexandre Kauskot
- INSERM UMR_S1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Dominique Lasne
- INSERM UMR_S1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,Necker Children's Hospital, Biological Hematology Service, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Carsten Janke
- Institut Curie, CNRS UMR3348, PSL Research University, Orsay, France.,Institut Curie, CNRS UMR3348, Université Paris Sud, Université Paris-Saclay, Orsay, France
| | - Kathiresan Natarajan
- Institut Curie, CNRS UMR3348, PSL Research University, Orsay, France.,Institut Curie, CNRS UMR3348, Université Paris Sud, Université Paris-Saclay, Orsay, France
| | - Alain Schmitt
- INSERM U1016, Faculté de Médecine, Cochin Institute, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Christine Bole-Feysot
- Genomic Platform, INSERM UMR 1163, IMAGINE Institute, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Patrick Nitschke
- Bioinformatics Platform, IMAGINE Institute, Paris Descartes University, Paris, France
| | - Juliane Léger
- RARE Disorder Center: Centre des Maladies Endocriniennes Rares de la Croissance et du Développement, Paris, France.,Pediatric Endocrinology Unit, Hôpital Universitaire Robert Debré, AP-HP, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, Paris, France.,INSERM UMR 1141, DHU Protect, Paris, France
| | - Fabienne Jabot-Hanin
- Bioinformatics Platform, IMAGINE Institute, Paris Descartes University, Paris, France
| | - Frédéric Tores
- Bioinformatics Platform, IMAGINE Institute, Paris Descartes University, Paris, France
| | - Anita Michel
- INSERM, EFS Grand Est, BPPS UMR-S 1255, FMTS, Université de Strasbourg, Strasbourg, France
| | - Arnold Munnich
- INSERM U1163, IMAGINE Institute, Translational Genetics, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,Department of Genetics, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - Claude Besmond
- INSERM U1163, IMAGINE Institute, Translational Genetics, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Raphaël Scharfmann
- INSERM U1016, Faculté de Médecine, Cochin Institute, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - François Lanza
- INSERM, EFS Grand Est, BPPS UMR-S 1255, FMTS, Université de Strasbourg, Strasbourg, France
| | - Delphine Borgel
- INSERM UMR_S1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France.,Necker Children's Hospital, Biological Hematology Service, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Michel Polak
- INSERM U1016, Faculté de Médecine, Cochin Institute, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,IMAGINE Institute Affiliate, Paris, France.,RARE Disorder Center: Centre des Maladies Endocriniennes Rares de la Croissance et du Développement, Paris, France.,Pediatric Endocrinology, Gynecology and Diabetology Unit, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Paris, France.,Fédération Parisienne pour le Dépistage et la Prévention des Handicaps de l'Enfant (FPDPHE), Paris, France
| | - Aurore Carré
- INSERM U1016, Faculté de Médecine, Cochin Institute, Université Paris Descartes, Sorbonne Paris Cité, Paris, France .,IMAGINE Institute Affiliate, Paris, France.,RARE Disorder Center: Centre des Maladies Endocriniennes Rares de la Croissance et du Développement, Paris, France
| |
Collapse
|
24
|
Dupont A, Soukaseum C, Cheptou M, Adam F, Nipoti T, Lourenco-Rodrigues MD, Legendre P, Proulle V, Rauch A, Kawecki C, Bryckaert M, Rosa JP, Paris C, Ternisien C, Boisseau P, Goudemand J, Borgel D, Lasne D, Maurice P, Lenting PJ, Denis CV, Susen S, Kauskot A. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence. Haematologica 2019; 104:2493-2500. [PMID: 30819911 PMCID: PMC6959185 DOI: 10.3324/haematol.2018.206250] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Accepted: 02/26/2019] [Indexed: 11/13/2022] Open
Abstract
Patients with type 2B von Willebrand disease (vWD) (caused by gain-of-function mutations in the gene coding for von Willebrand factor) display bleeding to a variable extent and, in some cases, thrombocytopenia. There are several underlying causes of thrombocytopenia in type 2B vWD. It was recently suggested that desialylation-mediated platelet clearance leads to thrombocytopenia in this disease. However, this hypothesis has not been tested in vivo. The relationship between platelet desialylation and the platelet count was probed in 36 patients with type 2B von Willebrand disease (p.R1306Q, p.R1341Q, and p.V1316M mutations) and in a mouse model carrying the severe p.V1316M mutation (the 2B mouse). We observed abnormally high elevated levels of platelet desialylation in both patients with the p.V1316M mutation and the 2B mice. In vitro, we demonstrated that 2B p.V1316M/von Willebrand factor induced more desialylation of normal platelets than wild-type von Willebrand factor did. Furthermore, we found that N-glycans were desialylated and we identified αIIb and β3 as desialylation targets. Treatment of 2B mice with sialidase inhibitors (which correct platelet desialylation) was not associated with the recovery of a normal platelet count. Lastly, we demonstrated that a critical platelet desialylation threshold (not achieved in either 2B patients or 2B mice) was required to induce thrombocytopenia in vivo. In conclusion, in type 2B vWD, platelet desialylation has a minor role and is not sufficient to mediate thrombocytopenia.
Collapse
Affiliation(s)
- Annabelle Dupont
- Université de Lille, UMR Inserm 1011, Institut Pasteur de Lille, EGID, F-59000 Lille.,Department of Hematology, CHU de Lille, F-59000 Lille
| | - Christelle Soukaseum
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Mathilde Cheptou
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Frédéric Adam
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Thomas Nipoti
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | | | - Paulette Legendre
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Valérie Proulle
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre.,AP-HP, Department of Biological Hematology, CHU Bicêtre, Hôpitaux Universitaires Paris Sud, F-94270 Paris
| | - Antoine Rauch
- Université de Lille, UMR Inserm 1011, Institut Pasteur de Lille, EGID, F-59000 Lille.,Department of Hematology, CHU de Lille, F-59000 Lille
| | - Charlotte Kawecki
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Marijke Bryckaert
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Jean-Philippe Rosa
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Camille Paris
- Department of Hematology, CHU de Lille, F-59000 Lille
| | | | | | - Jenny Goudemand
- Université de Lille, UMR Inserm 1011, Institut Pasteur de Lille, EGID, F-59000 Lille.,Department of Hematology, CHU de Lille, F-59000 Lille
| | - Delphine Borgel
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre.,AP-HP, Department of Biological Hematology, Hôpital Necker, F-75015 Paris
| | - Dominique Lasne
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre.,AP-HP, Department of Biological Hematology, Hôpital Necker, F-75015 Paris
| | - Pascal Maurice
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Team 2 "Matrix aging and Vascular remodelling", Université de Reims Champagne Ardenne (URCA), UFR Sciences Exactes et Naturelles, F-51000 Reims, France
| | - Peter J Lenting
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Cécile V Denis
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| | - Sophie Susen
- Université de Lille, UMR Inserm 1011, Institut Pasteur de Lille, EGID, F-59000 Lille.,Department of Hematology, CHU de Lille, F-59000 Lille
| | - Alexandre Kauskot
- HITh, UMR_S 1176, INSERM Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre
| |
Collapse
|
25
|
Abdul Mudalip SK, Abu Bakar MR, Jamal P, Adam F. Prediction of Mefenamic Acid Solubility and Molecular Interaction Energies in Different Classes of Organic Solvents and Water. Ind Eng Chem Res 2018. [DOI: 10.1021/acs.iecr.8b02722] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Siti K. Abdul Mudalip
- Centre of Excellence for Advanced Research in Fluid Flow, Faculty of Chemical & Natural Resources Engineering, University Malaysia Pahang, Gambang, Kuantan, Pahang 26300, Malaysia
| | - Mohd R. Abu Bakar
- Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia, Bandar Indera Mahkota, Kuantan 25200, Pahang Malaysia
| | - P. Jamal
- Department of Biotechnology Engineering, Kulliyyah of Engineering, International Islamic University Malaysia, Kuala Lumpur 50728, Malaysia
| | - F. Adam
- Centre of Excellence for Advanced Research in Fluid Flow, Faculty of Chemical & Natural Resources Engineering, University Malaysia Pahang, Gambang, Kuantan, Pahang 26300, Malaysia
| |
Collapse
|
26
|
Kauskot A, Pascreau T, Adam F, Bruneel A, Reperant C, Lourenco-Rodrigues MD, Rosa JP, Petermann R, Maurey H, Auditeau C, Lasne D, Denis CV, Bryckaert M, de Lonlay P, Lavenu-Bombled C, Melki J, Borgel D. A mutation in the gene coding for the sialic acid transporter SLC35A1 is required for platelet life span but not proplatelet formation. Haematologica 2018; 103:e613-e617. [PMID: 30115659 DOI: 10.3324/haematol.2018.198028] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Affiliation(s)
- Alexandre Kauskot
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex
| | - Tiffany Pascreau
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex.,AP-HP, Department of Biological Hematology, Hôpital Necker, Paris
| | - Frédéric Adam
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex
| | - Arnaud Bruneel
- AP-HP, Biochemistry, Bichat University Hospital, Paris; INSERM UMR-1193, Université Paris-Sud, Châtenay-Malabry
| | - Christelle Reperant
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex
| | | | - Jean-Philippe Rosa
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex
| | | | - Hélène Maurey
- AP-HP, Department of Paediatric Neurology, Hôpital Bicêtre, Le Kremlin-Bicêtre
| | - Claire Auditeau
- AP-HP, Department of Biological Hematology, CHU Bicêtre, Hôpitaux Universitaires Paris Sud, Le Kremlin-Bicêtre
| | - Dominique Lasne
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex.,AP-HP, Department of Biological Hematology, Hôpital Necker, Paris
| | - Cécile V Denis
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex
| | - Marijke Bryckaert
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex
| | - Pascale de Lonlay
- AP-HP, Reference Center of Inherited Metabolic Diseases, Hôpital Necker, Université Paris Descartes
| | - Cécile Lavenu-Bombled
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex.,AP-HP, Department of Biological Hematology, CHU Bicêtre, Hôpitaux Universitaires Paris Sud, Le Kremlin-Bicêtre
| | - Judith Melki
- INSERM UMR-1169, University Paris Sud, Le Kremlin Bicêtre, France
| | - Delphine Borgel
- HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre cedex.,AP-HP, Department of Biological Hematology, Hôpital Necker, Paris
| |
Collapse
|
27
|
Adam F, Kauskot A, Kurowska M, Goudin N, Munoz I, Bordet JC, Huang JD, Bryckaert M, Fischer A, Borgel D, de Saint Basile G, Christophe OD, Ménasché G. Kinesin-1 Is a New Actor Involved in Platelet Secretion and Thrombus Stability. Arterioscler Thromb Vasc Biol 2018. [PMID: 29519941 DOI: 10.1161/atvbaha.117.310373] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVE Platelet secretion is crucial for many physiological platelet responses. Even though several regulators of the fusion machinery for secretory granule exocytosis have been identified in platelets, the underlying mechanisms are not yet fully characterized. APPROACH AND RESULTS By studying a mouse model (cKO [conditional knockout]Kif5b) lacking Kif5b (kinesin-1 heavy chain) in its megakaryocytes and platelets, we evidenced unstable hemostasis characterized by an increase of blood loss associated to a marked tendency to rebleed in a tail-clip assay and thrombus instability in an in vivo thrombosis model. This instability was confirmed in vitro in a whole-blood perfusion assay under blood flow conditions. Aggregations induced by thrombin and collagen were also impaired in cKOKif5b platelets. Furthermore, P-selectin exposure, PF4 (platelet factor 4) secretion, and ATP release after thrombin stimulation were impaired in cKOKif5b platelets, highlighting the role of kinesin-1 in α-granule and dense granule secretion. Importantly, exogenous ADP rescued normal thrombin induced-aggregation in cKOKif5b platelets, which indicates that impaired aggregation was because of defective release of ADP and dense granules. Last, we demonstrated that kinesin-1 interacts with the molecular machinery comprising the granule-associated Rab27 (Ras-related protein Rab-27) protein and the Slp4 (synaptotagmin-like protein 4/SYTL4) adaptor protein. CONCLUSIONS Our results indicate that a kinesin-1-dependent process plays a role for platelet function by acting into the mechanism underlying α-granule and dense granule secretion.
Collapse
Affiliation(s)
- Frédéric Adam
- From the INSERM, UMR_S 1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France (F.A., A.K., M.B., D.B., O.D.C.)
| | - Alexandre Kauskot
- From the INSERM, UMR_S 1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France (F.A., A.K., M.B., D.B., O.D.C.)
| | - Mathieu Kurowska
- INSERM, UMR_S 1163, Laboratory of Normal and Pathological Homeostasis of the Immune System, Paris, France (M.K., I.M., A.F., G.d.S.B., G.M.).,Imagine Institute (M.K., I.M., A.F., G.d.S.B., G.M.)
| | - Nicolas Goudin
- Cell Imaging Facility, Imagine Institute (N.G.), Paris Descartes University, Sorbonne Paris Cité, France
| | - Isabelle Munoz
- INSERM, UMR_S 1163, Laboratory of Normal and Pathological Homeostasis of the Immune System, Paris, France (M.K., I.M., A.F., G.d.S.B., G.M.).,Imagine Institute (M.K., I.M., A.F., G.d.S.B., G.M.)
| | - Jean-Claude Bordet
- Laboratoire d'Hémostase, Centre de Biologie Est, Hospices Civils de Lyon, Bron, France (J.-C.B.).,Laboratoire de Recherche sur l'Hémophilie, UCBL1, Lyon, France (J.-C.B.)
| | - Jian-Dong Huang
- School of Biomedical Sciences, The University of Hong Kong, China (J.-D.H.)
| | - Marijke Bryckaert
- From the INSERM, UMR_S 1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France (F.A., A.K., M.B., D.B., O.D.C.)
| | - Alain Fischer
- INSERM, UMR_S 1163, Laboratory of Normal and Pathological Homeostasis of the Immune System, Paris, France (M.K., I.M., A.F., G.d.S.B., G.M.).,Imagine Institute (M.K., I.M., A.F., G.d.S.B., G.M.).,Department of Immunology and Pediatric Hematology (A.F.)
| | - Delphine Borgel
- From the INSERM, UMR_S 1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France (F.A., A.K., M.B., D.B., O.D.C.).,Biological Hematology Service (D.B.), Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, France; and Collège de France, Paris (A.F.)
| | - Geneviève de Saint Basile
- INSERM, UMR_S 1163, Laboratory of Normal and Pathological Homeostasis of the Immune System, Paris, France (M.K., I.M., A.F., G.d.S.B., G.M.).,Imagine Institute (M.K., I.M., A.F., G.d.S.B., G.M.)
| | - Olivier D Christophe
- From the INSERM, UMR_S 1176, Paris-Sud University, Université Paris-Saclay, Le Kremlin-Bicêtre, France (F.A., A.K., M.B., D.B., O.D.C.)
| | - Gaël Ménasché
- INSERM, UMR_S 1163, Laboratory of Normal and Pathological Homeostasis of the Immune System, Paris, France (M.K., I.M., A.F., G.d.S.B., G.M.).,Imagine Institute (M.K., I.M., A.F., G.d.S.B., G.M.)
| |
Collapse
|
28
|
Lemos A, Adam F, Moura K, Moraes L, Silva O. Histological and Histochemical Characterization of the Midgut of Healthy Aedes aegypti Larvae. ACTA ACUST UNITED AC 2018. [DOI: 10.9734/arrb/2018/37443] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Abstract
<p>The main objective of this work is to develop film and study the thermal characteristics of polysaccharides films at various concentration of carrageenan in the mixture by calculating activation energy of polysaccharides films. There were four (4) film samples of two polysaccharides combination; arabic gum (AG) and carrageenan (C) with different formulations; sample A, sample B, sample C and sample D prepared. Sample A film is the control sample that contained only arabic gum and distilled water (DI) with 40% weight arabic gum per volume DI water (w/v%). Meanwhile for sample B and C were prepared with concentration 40 w/v% of Arabic gum and two differents of carrageenan concentrations; 1 w/v% and 10 w/v% respectively. Polyethylene glycol 400 (PEG 400) as a plasticiser was added into sample D film. The sample films were thermally characterized using differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) under nitrogen atmosphere. The major thermal transitions as well as, activation energies of the major decomposition stages were determined. Sample A and B films exhibited the highest (112.43 kJ/mol) and the lowest (102.89 kJ/mol) activation energy of thermal decomposition, respectively. The activation energies were lower at larger amounts of sulfate groups from carrageenan on the degradation reactions. The DSC trend for all samples shows two (2) major intense peaks recorded in the DSC thermograms; an endothermic transition at temperature around 100<sup>°</sup>C and followed by an exothermic transition at temperature around 300<sup>°</sup>C. The endothermic transition is due to the heat absorption for dehydration of water, H2O and the decomposition of samples process. Meanwhile, the exothermic transition is caused by the formation of H<sub>2</sub>O, CO and CH<sub>4</sub> in polysaccharide film from dehydration, depolymerisation and decomposition at the high-temperature stages.</p><p>Chemical Engineering Research Bulletin 19(2017) 80-86</p>
Collapse
|
30
|
|
31
|
Aymé G, Adam F, Legendre P, Bazaa A, Proulle V, Denis CV, Christophe OD, Lenting PJ. A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report. Arterioscler Thromb Vasc Biol 2017. [PMID: 28642239 DOI: 10.1161/atvbaha.117.309319] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE von Willebrand factor (VWF) is crucial to hemostasis, but also plays a role in inflammatory processes. Unfortunately, no proper monoclonal antibodies to study VWF function in mice are currently available. We therefore aimed to generate single-domain antibodies (sdAbs) recognizing murine VWF and blocking its function in vivo. APPROACH AND RESULTS Llama-derived sdAbs recognizing both human and murine VWF were isolated via phage display technology. One of them (designated KB-VWF-006) recognized the VWF A1 domain with picomolar affinity. This sdAb avidity was strongly enhanced via dimerization using a triple Ala linker (KB-VWF-006bi). When administered in vivo to wild-type mice, KB-VWF-006bi dose dependently induced bleeding in a tail clip model. In 2 distinct models of inflammation, KB-VWF-006bi efficiently interfered with leukocyte recruitment and vascular leakage. CONCLUSIONS KB-VWF-006bi is an sdAb recognizing the A1 domain of human VWF and murine VWF that interferes with VWF-platelet interactions in vivo. By using this sdAb, we now also show that the A1 domain is pertinent to the participation of VWF in the inflammatory response.
Collapse
Affiliation(s)
- Gabriel Aymé
- From the Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France (G.A., F.A., P.L., A.B., V.P., C.V.D., O.D.C., P.J.L.); and Department of Biological Hematology, CHU Bicetre, Hôpitaux Universitaires Paris-Sud, AP-HP, France (V.P.)
| | - Frédéric Adam
- From the Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France (G.A., F.A., P.L., A.B., V.P., C.V.D., O.D.C., P.J.L.); and Department of Biological Hematology, CHU Bicetre, Hôpitaux Universitaires Paris-Sud, AP-HP, France (V.P.)
| | - Paulette Legendre
- From the Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France (G.A., F.A., P.L., A.B., V.P., C.V.D., O.D.C., P.J.L.); and Department of Biological Hematology, CHU Bicetre, Hôpitaux Universitaires Paris-Sud, AP-HP, France (V.P.)
| | - Amine Bazaa
- From the Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France (G.A., F.A., P.L., A.B., V.P., C.V.D., O.D.C., P.J.L.); and Department of Biological Hematology, CHU Bicetre, Hôpitaux Universitaires Paris-Sud, AP-HP, France (V.P.)
| | - Valérie Proulle
- From the Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France (G.A., F.A., P.L., A.B., V.P., C.V.D., O.D.C., P.J.L.); and Department of Biological Hematology, CHU Bicetre, Hôpitaux Universitaires Paris-Sud, AP-HP, France (V.P.)
| | - Cécile V Denis
- From the Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France (G.A., F.A., P.L., A.B., V.P., C.V.D., O.D.C., P.J.L.); and Department of Biological Hematology, CHU Bicetre, Hôpitaux Universitaires Paris-Sud, AP-HP, France (V.P.).
| | - Olivier D Christophe
- From the Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France (G.A., F.A., P.L., A.B., V.P., C.V.D., O.D.C., P.J.L.); and Department of Biological Hematology, CHU Bicetre, Hôpitaux Universitaires Paris-Sud, AP-HP, France (V.P.)
| | - Peter J Lenting
- From the Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France (G.A., F.A., P.L., A.B., V.P., C.V.D., O.D.C., P.J.L.); and Department of Biological Hematology, CHU Bicetre, Hôpitaux Universitaires Paris-Sud, AP-HP, France (V.P.)
| |
Collapse
|
32
|
Berrou E, Adam F, Lebret M, Planche V, Fergelot P, Issertial O, Coupry I, Bordet JC, Nurden P, Bonneau D, Colin E, Goizet C, Rosa JP, Bryckaert M. Gain-of-Function Mutation in Filamin A Potentiates Platelet Integrin α IIbβ 3 Activation. Arterioscler Thromb Vasc Biol 2017; 37:1087-1097. [PMID: 28428218 DOI: 10.1161/atvbaha.117.309337] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Accepted: 03/31/2017] [Indexed: 12/20/2022]
Abstract
OBJECTIVE Dominant mutations of the X-linked filamin A (FLNA) gene are responsible for filaminopathies A, which are rare disorders including brain periventricular nodular heterotopia, congenital intestinal pseudo-obstruction, cardiac valves or skeleton malformations, and often macrothrombocytopenia. APPROACH AND RESULTS We studied a male patient with periventricular nodular heterotopia and congenital intestinal pseudo-obstruction, his unique X-linked FLNA allele carrying a stop codon mutation resulting in a 100-amino acid-long FLNa C-terminal extension (NP_001447.2: p.Ter2648SerextTer101). Platelet counts were normal, with few enlarged platelets. FLNa was detectable in all platelets but at 30% of control levels. Surprisingly, all platelet functions were significantly upregulated, including platelet aggregation and secretion, as induced by ADP, collagen, or von Willebrand factor in the presence of ristocetin, as well as thrombus formation in blood flow on a collagen or on a von Willebrand factor matrix. Most importantly, patient platelets stimulated with ADP exhibited a marked increase in αIIbβ3 integrin activation and a parallel increase in talin recruitment to β3, contrasting with normal Rap1 activation. These results are consistent with the mutant FLNa affecting the last step of αIIbβ3 activation. Overexpression of mutant FLNa in the HEL megakaryocytic cell line correlated with an increase (compared with wild-type FLNa) in PMA-induced fibrinogen binding to and in talin and kindlin-3 recruitment by αIIbβ3. CONCLUSIONS Altogether, our results are consistent with a less binding of mutant FLNa to β3 and the facilitated recruitment of talin by β3 on platelet stimulation, explaining the increased αIIbβ3 activation and the ensuing gain-of-platelet functions.
Collapse
Affiliation(s)
- Eliane Berrou
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Frédéric Adam
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Marilyne Lebret
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Virginie Planche
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Patricia Fergelot
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Odile Issertial
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Isabelle Coupry
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Jean-Claude Bordet
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Paquita Nurden
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Dominique Bonneau
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Estelle Colin
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Cyril Goizet
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Jean-Philippe Rosa
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.)
| | - Marijke Bryckaert
- From the INSERM UMR_S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France (E.B., F.A., M.L., V.P., O.I., J.-P.R., M.B.); INSERM UMR_S 1211, Université de Bordeaux, CHU Bordeaux UNIV EA 4576, Place Aurélie Raba-Léon, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Place Aurélie Raba-Léon, France (P.F., C.G.); Unité d'Hémostase Biologique, Hospices Civils de Lyon, CBE Bron, EA4609 and CIQLE-Lyon Bio Image, Université Lyon, France (J.-C.B.); Institut Hospitalo-Universitaire LIRYC PTIB, Hôpital Xavier Arnozan, av du Haut Lévêque, Pessac, France (P.N.); and Département de Biochimie et Génétique, INSERM UMR_S 1083 - CNRS 6214, CHU Angers, Angers, France (D.B., E.C.).
| |
Collapse
|
33
|
Pepin M, Mezouar S, Pegon J, Muczynski V, Adam F, Bianchini EP, Bazaa A, Proulle V, Rupin A, Paysant J, Panicot-Dubois L, Christophe OD, Dubois C, Lenting PJ, Denis CV. Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity. Sci Rep 2016; 6:37953. [PMID: 27892504 PMCID: PMC5125011 DOI: 10.1038/srep37953] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Accepted: 11/01/2016] [Indexed: 01/21/2023] Open
Abstract
Interactions between endothelial selectins and the leukocyte counter-receptor PSGL1 mediates leukocyte recruitment to inflammation sites. PSGL1 is highly sialylated, making it a potential ligand for Siglec-5, a leukocyte-receptor that recognizes sialic acid structures. Binding assays using soluble Siglec-5 variants (sSiglec-5/C4BP and sSiglec-5/Fc) revealed a dose- and calcium-dependent binding to PSGL1. Pre-treatment of PSGL1 with sialidase reduced Siglec-5 binding by 79 ± 4%. In confocal immune-fluorescence assays, we observed that 50% of Peripheral Blood Mononuclear Cells (PBMCs) simultaneously express PSGL1 and Siglec-5. Duolink-proximity ligation analysis demonstrated that PSGL1 and Siglec-5 are in close proximity (<40 nm) in 31 ± 4% of PBMCs. In vitro perfusion assays revealed that leukocyte-rolling over E- and P-selectin was inhibited by sSiglec-5/Fc or sSiglec-5/C4BP, while adhesion onto VCAM1 was unaffected. When applied to healthy mice (0.8 mg/kg), sSiglec-5/C4BP significantly reduced the number of rolling leukocytes under basal conditions (10.9 ± 3.7 versus 23.5 ± 9.3 leukocytes/field/min for sSiglec-5/C4BP-treated and control mice, respectively; p = 0.0093). Moreover, leukocyte recruitment was inhibited over a 5-h observation period in an in vivo model of TNFalpha-induced inflammation following injection sSiglec-5/C4BP (0.8 mg/kg). Our data identify PSGL1 as a ligand for Siglec-5, and soluble Siglec-5 variants appear efficient in blocking PSGL1-mediated leukocyte rolling and the inflammatory response in general.
Collapse
Affiliation(s)
- Marion Pepin
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Soraya Mezouar
- Aix Marseille Université, Inserm UMR_S 1076, (VRCM) Vascular Research Center of Marseille, 13385 Marseille, France
| | - Julie Pegon
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Vincent Muczynski
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Frédéric Adam
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Elsa P Bianchini
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Amine Bazaa
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Valerie Proulle
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France.,Department of Biological Hematology, CHU Bicetre, Hopitaux Universitaires Paris Sud, AP-HP, Paris, France
| | - Alain Rupin
- Institut de Recherche International Servier, Recherche Translationelle et Clinique Oncologie, 92150, Suresnes, France
| | - Jerome Paysant
- Institut de Recherches Servier, Unité de Recherche et de Découverte Cardiovasculaire, 92150, Suresnes, France
| | - Laurence Panicot-Dubois
- Aix Marseille Université, Inserm UMR_S 1076, (VRCM) Vascular Research Center of Marseille, 13385 Marseille, France
| | - Olivier D Christophe
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Christophe Dubois
- Aix Marseille Université, Inserm UMR_S 1076, (VRCM) Vascular Research Center of Marseille, 13385 Marseille, France
| | - Peter J Lenting
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Cécile V Denis
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| |
Collapse
|
34
|
Kauskot A, Poirault-Chassac S, Adam F, Muczynski V, Aymé G, Casari C, Bordet JC, Soukaseum C, Rothschild C, Proulle V, Pietrzyk-Nivau A, Berrou E, Christophe OD, Rosa JP, Lenting PJ, Bryckaert M, Denis CV, Baruch D. LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B. JCI Insight 2016; 1:e88643. [PMID: 27734030 DOI: 10.1172/jci.insight.88643] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
von Willebrand disease type 2B (VWD-type 2B) is characterized by gain-of-function mutations of von Willebrand factor (vWF) that enhance its binding to platelet glycoprotein Ibα and alter the protein's multimeric structure. Patients with VWD-type 2B display variable extents of bleeding associated with macrothrombocytopenia and sometimes with thrombopathy. Here, we addressed the molecular mechanism underlying the severe macrothrombocytopenia both in a knockin murine model for VWD-type 2B by introducing the p.V1316M mutation in the murine Vwf gene and in a patient bearing this mutation. We provide evidence of a profound defect in megakaryocyte (MK) function since: (a) the extent of proplatelet formation was drastically decreased in 2B MKs, with thick proplatelet extensions and large swellings; and (b) 2B MKs presented actin disorganization that was controlled by upregulation of the RhoA/LIM kinase (LIMK)/cofilin pathway. In vitro and in vivo inhibition of the LIMK/cofilin signaling pathway rescued actin turnover and restored normal proplatelet formation, platelet count, and platelet size. These data indicate, to our knowledge for the first time, that the severe macrothrombocytopenia in VWD-type 2B p.V1316M is due to an MK dysfunction that originates from a constitutive activation of the RhoA/LIMK/cofilin pathway and actin disorganization. This suggests a potentially new function of vWF during platelet formation that involves regulation of actin dynamics.
Collapse
Affiliation(s)
- Alexandre Kauskot
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France.,INSERM UMR-S 1140, Univ Paris Descartes, Sorbonne Paris Cité, Paris, France
| | | | - Frédéric Adam
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Vincent Muczynski
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Gabriel Aymé
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Caterina Casari
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Jean-Claude Bordet
- Laboratoire d'Hémostase, Hôpital Edouard Herriot, Lyon, France.,Laboratoire de Recherche sur l'Hémophilie, UCBL1, Faculté de Médecine Lyon-Est, Lyon, France
| | - Christelle Soukaseum
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | | | - Valérie Proulle
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France.,Department of Biological Hematology, CHU Bicêtre, Hôpitaux Universitaires Paris Sud, AP-HP, Paris, France
| | | | - Eliane Berrou
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Olivier D Christophe
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Jean-Philippe Rosa
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Peter J Lenting
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Marijke Bryckaert
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Cécile V Denis
- INSERM UMR-S 1176, Univ Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France
| | - Dominique Baruch
- INSERM UMR-S 1140, Univ Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
35
|
Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, Raicher I, Üçeyler N, Sommer C, Bouhassira D. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2016; 15:555-65. [DOI: 10.1016/s1474-4422(16)00017-x] [Citation(s) in RCA: 136] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Revised: 01/11/2016] [Accepted: 01/13/2016] [Indexed: 01/22/2023]
|
36
|
|
37
|
Simoni M, Kuhn EP, Morf LS, Kuendig R, Adam F. Urban mining as a contribution to the resource strategy of the Canton of Zurich. Waste Manag 2015; 45:10-21. [PMID: 26159044 DOI: 10.1016/j.wasman.2015.06.045] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Revised: 06/28/2015] [Accepted: 06/30/2015] [Indexed: 06/04/2023]
Abstract
Urban mining is increasingly being recognised as an important component of resource strategies of public authorities, not only because it contributes to environmental protection, but also because it is a source of valuable recyclable materials. We demonstrate that the sustainable livelihoods (SL) framework can be used for public policy making in waste management by presenting the approach and experiences of a review study termed 'urban mining potential analysis' and its application to antimony, copper, gypsum, gold and rare earth elements. This article uses the rare earth element (REE) group to illustrate and present an overview over information and knowledge gaps concerning urban mining. The analysis shows that rare earth element recycling can be more environmentally friendly than primary production, particularly if the latter comes from countries with weak enforcement of environmental legislation. On the other hand REE recycling often cannot compete with large scale primary production because market prices do not reflect the social and environmental impacts of production, and because the avoided impacts of waste decontamination and reduced waste production are not considered. The urban mining potential analysis can be used to support decision making and the setting of priorities for future research and public action. The findings of the study and expert opinions based thereon contribute to the selection of measures and the formulation of public waste management and resource strategies in general.
Collapse
Affiliation(s)
- M Simoni
- SGTK, Swiss Geotechnical Commission, c/o Federal Institute of Technology ETH Zurich, Sonneggstrasse 5, 8092 Zurich, Switzerland.
| | - E P Kuhn
- Office for Waste Management, Environmental Protection Agency of Canton Zurich (AWEL Zurich), Weinbergstrasse 34, 8090 Zurich, Switzerland
| | - L S Morf
- Office for Waste Management, Environmental Protection Agency of Canton Zurich (AWEL Zurich), Weinbergstrasse 34, 8090 Zurich, Switzerland
| | - R Kuendig
- SGTK, Swiss Geotechnical Commission, c/o Federal Institute of Technology ETH Zurich, Sonneggstrasse 5, 8092 Zurich, Switzerland
| | - F Adam
- Office for Waste Management, Environmental Protection Agency of Canton Zurich (AWEL Zurich), Weinbergstrasse 34, 8090 Zurich, Switzerland
| |
Collapse
|
38
|
O'Reilly S, Kumar A, Adam F. The role of hierarchical production planning in food manufacturing SMEs. International Journal of Operations & Production Management 2015. [DOI: 10.1108/ijopm-04-2014-0157] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose
– In recent years there has been an increasing interest in make-to-stock and make-to-order combined strategies in food manufacturing operations. However, most scholarly work to-date has neglected the role of hierarchical production planning (HPP) in guiding small- and medium-sized enterprise (SME) implementation of such strategies. The purpose of this paper is to address food SME manufacturers’ readiness to adopt such strategies, in terms of internal integration and their capability to adopt formalised planning approaches.
Design/methodology/approach
– This study adopted an action research methodology to explore the potential impact of HPP in SME food manufacturers. Selected companies had identified product variety management as a challenge and also had recognised the need to enhance internal integration. Given this, the research team, from a theoretical perspective, proposed the use of HPP set within a broader decision-making conceptual framework to improve internal integration and planning.
Findings
– This paper adopts the fundamental position that HPP provides a useful framework in the establishment of strategic and tactical level constraints and priorities which then act as specific guides at the operational level, and presents empirical evidence in a food SME manufacturing context. In the cases the authors studies, the cascading effect of this decision-making framework focused attention on key metrics, encouraged greater internal integration and delivered tangible, significant improvements in performance. This was greatly facilitated by the provision of new key data on the cost of certain managerial trade-offs which these firms faced.
Originality/value
– SMEs are of a scale that requires a formalised planning approach; however production planning systems are typically designed for large scale enterprises. This paper addresses the need of SMEs in this regard. Well-established supply chain metrics were used to establish the benefits of both HPP and resulting improvement in internal integration and beyond, in terms of improvement in the quality of planning decisions.
Collapse
|
39
|
|
40
|
De Sutter P, Day J, Adam F. Qui sont les femmes orgasmiques ? Étude exploratoire sur un échantillon de femmes francophones tout venant. Sexologies 2014. [DOI: 10.1016/j.sexol.2014.04.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
41
|
|
42
|
Hervé D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S, Bergametti F, Essongue A, Berrou E, Krivosic V, Sainte-Rose C, Houdart E, Adam F, Billiemaz K, Lebret M, Roman S, Passemard S, Boulday G, Delaforge A, Guey S, Dray X, Chabriat H, Brouckaert P, Bryckaert M, Tournier-Lasserve E. Loss of α1β1 Soluble Guanylate Cyclase, the Major Nitric Oxide Receptor, Leads to Moyamoya and Achalasia. Am J Hum Genet 2014. [DOI: 10.1016/j.ajhg.2014.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
43
|
Hervé D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S, Bergametti F, Essongue A, Berrou E, Krivosic V, Sainte-Rose C, Houdart E, Adam F, Billiemaz K, Lebret M, Roman S, Passemard S, Boulday G, Delaforge A, Guey S, Dray X, Chabriat H, Brouckaert P, Bryckaert M, Tournier-Lasserve E. Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet 2014; 94:385-94. [PMID: 24581742 DOI: 10.1016/j.ajhg.2014.01.018] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2013] [Accepted: 01/31/2014] [Indexed: 12/09/2022] Open
Abstract
Moyamoya is a cerebrovascular condition characterized by a progressive stenosis of the terminal part of the internal carotid arteries (ICAs) and the compensatory development of abnormal "moyamoya" vessels. The pathophysiological mechanisms of this condition, which leads to ischemic and hemorrhagic stroke, remain unknown. It can occur as an isolated cerebral angiopathy (so-called moyamoya disease) or in association with various conditions (moyamoya syndromes). Here, we describe an autosomal-recessive disease leading to severe moyamoya and early-onset achalasia in three unrelated families. This syndrome is associated in all three families with homozygous mutations in GUCY1A3, which encodes the α1 subunit of soluble guanylate cyclase (sGC), the major receptor for nitric oxide (NO). Platelet analysis showed a complete loss of the soluble α1β1 guanylate cyclase and showed an unexpected stimulatory role of sGC within platelets. The NO-sGC-cGMP pathway is a major pathway controlling vascular smooth-muscle relaxation, vascular tone, and vascular remodeling. Our data suggest that alterations of this pathway might lead to an abnormal vascular-remodeling process in sensitive vascular areas such as ICA bifurcations. These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.
Collapse
|
44
|
Ciampi de Andrade D, Mhalla A, Adam F, Texeira MJ, Bouhassira D. Repetitive transcranial magnetic stimulation induced analgesia depends on N-methyl-d-aspartate glutamate receptors. Pain 2014; 155:598-605. [DOI: 10.1016/j.pain.2013.12.022] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2013] [Revised: 12/03/2013] [Accepted: 12/10/2013] [Indexed: 12/21/2022]
|
45
|
Casari C, Berrou E, Lebret M, Adam F, Kauskot A, Bobe R, Desconclois C, Fressinaud E, Christophe OD, Lenting PJ, Rosa JP, Denis CV, Bryckaert M. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3. J Clin Invest 2013; 123:5071-81. [PMID: 24270421 DOI: 10.1172/jci69458] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 09/09/2013] [Indexed: 12/16/2022] Open
Abstract
von Willebrand disease type 2B (vWD-type 2B) is characterized by gain-of-function mutations in von Willebrand factor (vWF) that enhance its binding to the glycoprotein Ib-IX-V complex on platelets. Patients with vWD-type 2B have a bleeding tendency that is linked to loss of vWF multimers and/or thrombocytopenia. In this study, we uncovered evidence that platelet dysfunction is a third possible mechanism for bleeding tendency. We found that platelet aggregation, secretion, and spreading were diminished due to inhibition of integrin αIIbβ3 in platelets from mice expressing a vWD-type 2B-associated vWF (vWF/p.V1316M), platelets from a patient with the same mutation, and control platelets pretreated with recombinant vWF/p.V1316M. Impaired platelet function coincided with reduced thrombus growth. Further, αIIbβ3 activation and activation of the small GTPase Rap1 were impaired by vWF/p.V1316M following exposure to platelet agonists (thrombin, ADP, or convulxin). Conversely, thrombin- or ADP-induced Ca2+ store release, which is required for αIIbβ3 activation, was normal, indicating that vWF/p.V1316M acts downstream of Ca2+ release and upstream of Rap1. We found normal Syk phosphorylation and PLCγ2 activation following collagen receptor signaling, further implying that vWF/p.V1316M acts directly on or downstream of Ca2+ release. These data indicate that the vWD-type 2B mutation p.V1316M is associated with severe thrombocytopathy, which likely contributes to the bleeding tendency in vWD-type 2B.
Collapse
|
46
|
Blundell R, Adam F. Haemolytic anaemia and acute pancreatitis associated with zinc toxicosis in a dog. Vet rec case rep 2013. [DOI: 10.1136/vetreccr.100376rep] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- R. Blundell
- Veterinary PathologySchool of Veterinary ScienceUniversity of LiverpoolChester High RoadNestonCH64 7TEUK
| | - F. Adam
- Small Animal Teaching HospitalSchool of Veterinary ScienceUniversity of LiverpoolChester High RoadNestonCH64 7TEUK
| |
Collapse
|
47
|
Csáki C, O'Brien L, Giller K, McCarthy J, Tan K, Adam F. The use of E‐Payment in the distribution of social welfare in Ireland. Transforming Government: People, Process and Policy 2013. [DOI: 10.1108/17506161311308142] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PurposeE‐Government programs often address problems such as institutional ineffectiveness, lack of transparency, or social exclusion. Financial exclusion and people's reliance on ineffective payment methods appear to be a well‐known problem world‐wide. Yet, despite the large number of related case studies and academic reports on the topic, little is understood about the impact governmental payment practices have on the financial behaviour of citizens. Few investigations address how governmental use of payment methods and related policies may impact citizen/consumer behaviour. Through investigating the move to E‐Payment based methods to replace the dominant use of cash and cheques in social welfare in Ireland, the purpose of this paper is to explore the recipient's view of this government project.Design/methodology/approachThe research is organized as an intrinsic case study where the unit of analysis is one large project. It aims at a rich description of one particular case by analysing data collected from two main sources of evidence: preliminary investigation is done by reviewing relevant documents, while primary data collection involved face‐to‐face surveys of social welfare recipients (using a short, structured questionnaire augmented with a few open‐ended questions).FindingsThe planning and execution of E‐Government programs often face barriers of mostly social and historical nature. As the results of this research indicate, these barriers might be hard to overcome as they are the result of certain behaviours and attitudes rooted in people's daily experience, such as their daily financial reality. Results also imply that the choice of an adequate E‐Payment method and migration scenario by governmental agencies will be crucial to the outcome. Implementation and education will also be critical.Originality/valueThis study reports on the influence governmental decisions related to social welfare payment methods may have on recipients' financial habits regarding the choice of payment options. It also shows how recipients' everyday experience and financial reality determine the way they relate to payment options.
Collapse
|
48
|
Berrou E, Adam F, Lebret M, Fergelot P, Kauskot A, Coupry I, Jandrot-Perrus M, Nurden A, Favier R, Rosa JP, Goizet C, Nurden P, Bryckaert M. Heterogeneity of Platelet Functional Alterations in Patients With Filamin A Mutations. Arterioscler Thromb Vasc Biol 2013; 33:e11-8. [DOI: 10.1161/atvbaha.112.300603] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
We examined platelet functions in 4 unrelated patients with filaminopathy A caused by dominant mutations of the X-linked filamin A (
FLNA
) gene.
Methods and Results—
Patients P1, P2, and P4 exhibited periventricular nodular heterotopia, heterozygozity for truncating
FLNA
mutations, and thrombocytopenia (except P2). P3 exhibited isolated thrombocytopenia and heterozygozity for a p.Glu1803Lys
FLNA
mutation. Truncated FLNa was undetectable by Western blotting of P1, P2, and P4 platelets, but full-length FLNa was detected at 37%, 82%, and 57% of control, respectively. P3 FLNa (p.Glu1803Lys and full-length) was assessed at 79%. All patients exhibited a platelet subpopulation negative for FLNa. Platelet aggregation, secretion, glycoprotein VI signaling, and thrombus growth on collagen were decreased for P1, P3, and P4, but normal for P2. For the 2 patients analyzed (P1 and P4), spreading was enhanced and, more markedly, in FLNa-negative platelets, suggesting that FLNa negatively regulates cytoskeleton reorganization. Platelet adhesion to von Willebrand factor under flow correlated with platelet full-length FLNa content: markedly reduced for P1 and P4 and unchanged for P2. Interestingly, von Willebrand factor flow adhesion was increased for P3, consistent with a gain-of-function effect enhancing glycoprotein Ib-IX-V/von Willebrand factor interaction. These results are consistent with a positive role for FLNa in platelet adhesion under high shear.
Conclusion—
FLNA
mutation heterogeneity correlates with different platelet functional impacts and points to opposite regulatory roles of FLNa in spreading and flow adhesion under shear.
Collapse
Affiliation(s)
- Eliane Berrou
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Frédéric Adam
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Marilyne Lebret
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Patricia Fergelot
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Alexandre Kauskot
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Isabelle Coupry
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Martine Jandrot-Perrus
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Alan Nurden
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Rémi Favier
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Jean-Philippe Rosa
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Cyril Goizet
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Paquita Nurden
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Marijke Bryckaert
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| |
Collapse
|
49
|
Abstract
We describe a case of zinc toxicity in a 14-month-old, female, neutered, Cavalier King Charles spaniel with a 48-hour history of haematochezia, icterus and collapse. Regenerative anaemia with a packed-cell volume of 7 per cent was seen. Prior to referral, radiography had revealed a gastric, metallic foreign body which was removed at exploratory laparotomy. On presentation, the dog was comatose, hypothermic and bradycardic - resuscitation was performed successfully, but the dog then displayed marked abdominal pain. The dog died 12 hours after presentation. At postmortem examination, the animal showed severe icterus. Both kidneys were diffusely dark red; the pancreas was diffusely pale and nodular. Histopathological examination revealed evidence of intravascular haemolysis with blood vessel lumens containing haemoglobin. The renal tubules also contained large amounts of intraluminal haemoglobin with haemoglobin crystals scattered throughout the cortex and medulla. The pancreas exhibited multifocal coagulative necrosis, surrounded by a neutrophil-dominated inflammatory infiltrate. Zinc levels were markedly increased above the normal reference range in both liver and kidney. This report describes the clinical and pathological findings of a case of acute zinc toxicity in a dog following ingestion of a metallic object which resulted in marked haemolytic anaemia and acute pancreatitis.
Collapse
Affiliation(s)
- R Blundell
- Veterinary Pathology, School of Veterinary Science, University of Liverpool, Chester High Road, Neston, CH64 7TE, UK.
| | | |
Collapse
|
50
|
Adam F, Pelle-Lancien E, Bauer T, Solignac N, Sessler D, Chauvin M. Anesthesia and postoperative analgesia after percutaneous hallux valgus repair in ambulatory patients. ACTA ACUST UNITED AC 2012; 31:e265-8. [DOI: 10.1016/j.annfar.2012.07.022] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Accepted: 07/26/2012] [Indexed: 11/26/2022]
|